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ABSTRACT 
Elucidating the Role of the α7 Nicotinic Receptor in the Etiology of Schizophrenia 
by 
Michelle J. Chandley 
The α7 subunit of the nicotinic receptor, a ligand gated ion channel with an 
affinity for nicotine, has long been implicated in the pathophysiology of 
schizophrenia due to the extremely high rate of smoking within the patient 
population.  However, the exact role of the receptor has never fully been 
determined.  In the following studies, various functions the receptor may assume 
in disease state are evaluated.  There is a strong relationship between the 
immune system and schizophrenia, with the α7 subunit possibly serving as the 
link between the two.  One of the following studies looks at the possibility of the 
receptor functioning as antigen in an autoimmune response.   Blood sera of 
schizophrenic patients, as well as controls, were analyzed for the presence of 
antibodies to the α7 subunit of the nicotinic receptor.  A sensitive ligand-based 
assay revealed schizophrenic patients could possess a pathogenic level of 
antibody that may exacerbate the degenerative nature of the disease, allowing 
for the possibility that receptor antibodies may serve as a contributing factor in 
the etiology of the disorder in at least a subset of patients.  In other studies, the 
expression of the α7 receptor was investigated.  Recombinant α7 receptor 
production has eluded researchers in non-mammalian species and this was the 
focus of our initial studies.  In general, the lack of sufficient molecular 
recombinant techniques utilizing the receptor makes characterization of the α7 
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receptor and it’s specific protein interactions difficult to evaluate.  The regulatory 
mechanisms of the nicotinic receptor α7 subunit production and receptor 
formation have yet to be completely elucidated.   Results in this investigation 
found a relationship between a functional CRE-element in the promoter region.     
  
 4 
DEDICATION 
 
This dissertation is dedicated to my nephew Lee Herman Chandley, III 
whose battle with autism inspired me to actively join in the fight for new 
information in improving the prognosis for all those afflicted with mental illness. 
 5 
ACKNOWLEDGEMENTS 
 
First, I would like to express my deepest appreciation to my chair, 
Professor Barney Miller.  He has graciously provided me with every opportunity 
necessary to fully develop my professional education in many areas.   
 
I would like to thank my committee members, Dr. Ron Baisden, Dr. 
Antonio Rusinol, Dr. Greg Ordway, and Dr. Merry Miller for all the time they have 
invested in me, especially through insurmountable work schedules of their own. 
 
I would also like to thank everyone involved in the professional 
development of all the students in the Biomedical Science Program, but in 
particular Beverly Sherwood and Professor Mitchell Robinson for their tireless 
devotion to us.  
  
Also, my sincere gratitude goes to two very special people whose 
immediate guidance and help has made this a wonderful journey.  Tracy Wilson, 
with her expertise and determination, has taught me so much about the technical 
side of science, as well as made day-to-day life in the laboratory a pleasure.  
Christine Newell, whose inspiration through her own journey, has guided me in 
many of the choices I have made.       
 
I would especially like to thank my mother, grandmother, and everyone 
who helped to ensure my family has been taken care of during those extra times 
I have had to be at the laboratory or at a computer screen.  
 
Last, but certainly not least, I want to acknowledge my Lord and Savior, 
Jesus Christ, who has blessed me with all His gifts to make a difference in the 
world today.   
 6 
CONTENTS 
 
 Page 
ABSTRACT ............................................................................................................  2 
DEDICATION .........................................................................................................  4 
ACKNOWLEDGEMENTS .......................................................................................  5 
LIST OF TABLES....................................................................................................  9 
LIST OF FIGURES .................................................................................................  10 
Chapter 
 1. INTRODUCTION.............................................................................................  12 
Background..................................................................................................  12 
Epidemiology................................................................................................  14 
Diagnosis .....................................................................................................  15 
The Purpose of the α7 Subunit of the Nicotinic Receptor in Schizophrenia .  17 
Etiological Hypothesis of Schizophrenia ......................................................  26 
 Dysregulated Immune System................................................................  27 
 Dopaminergic Hypothesis .......................................................................  28 
 Cellular Neurodegeneration ....................................................................  30 
 Environmental Factors………. ................................................................  31 
 Genetic Contributions .............................................................................  32 
Specific Aims................................................................................................  33 
 2. MOLECULAR ADVANCES AND DISCOVERIES REGARDING THE α7 
RECEPTOR....................................................................................................  38 
Background..................................................................................................  38 
 History and Location of the α7 Nicotinic Receptor ..................................  38 
 Pathophysiology of the nAChRα7 Receptor ...........................................  39 
Molecular Biology of the nAChRα7 Receptor  .............................................  40 
 7 
 Protein Structure of the nAChRα7 Receptor ..........................................  40 
 Genetic Location.....................................................................................  44 
 Transcription of the CHRNA7 gene ........................................................  43 
 Post-translational Modifications to nAChRα7 Receptor ..........................  44 
 Assembly of nAChRα7 Receptors ..........................................................  45 
Pharmacological Significance of the nAChRα7 Receptor………………….. .  47 
Recombinant Expression of the nAChRα7 Receptor ………........................  48 
 Expression of nAChRα7 in Bacterial Expression Systems .....................  49 
 Expression of nAChRα7 in Yeast Expression Systems ..........................  50 
 Expression of nAChRα7 In Insect Expression Systems..........................  50 
 Expression of nAChRα7 in Mammalian Expression Systems.................  51 
 Expression of nAChRα7 in Cell-free Expression Systems......................  53 
 Expression of nAChRα7 in systems utilizing RIC-3 ................................  54 
 3.  INCREASED SERA ANTIBODIES FOR THE α7 SUBUNIT OF THE 
NICOTINIC RECEPTOR IN SCHIZOPHRENIA .............................................  55 
Background .................................................................................................  55 
Materials and Methods…………………………………………………………... 56 
 Patients...................................................................................................  56 
 ELISA using Recombinantly Expressed α7 Protein ................................  57 
 Determining Antibody Activities ..............................................................  58 
Results…………………………………………………………………………….. 59 
Discussion…………………………………………………………………………  62 
 4.  FUNCTIONAL CHARACTERIZATION OF THE CRE HALF-ELEMENT 
FOUND IN THE PROMOTER REGION OF THE NICOTINIC RECEPTOR 
α7 SUBUNIT ..................................................................................................  65 
Background..................................................................................................  65 
Materials and Methods…………………………………………………………... 67 
 8 
 Cell Culture .............................................................................................  67 
 EMSA......................................................................................................  67 
 Construction of Reporter Plasmid ...........................................................  68 
 Transfections and Reporter Gene Assay................................................  69 
 Chromatin Immunoprecipitation ..............................................................  69 
 Western Blot ...........................................................................................  71 
 RNA extraction and End point RT-PCR ..................................................  71 
Results…………………………………………………………………………….. 72 
 Ectopic CREB Protein Does Stimulate Expression of nAChRα7 ............  72 
 Binding of CREB to α7 Subunit of the Nicotinic Receptor.......................  73 
 Functionality of CRE Half-element in the CHRNA7 Promoter.................  79 
Discussion....................................................................................................  83 
 5. CONCLUDING REMARKS .............................................................................  88 
Recombinant Expression of the α7 Nicotinic Receptor ................................  88 
Autoimmunity in Schizophrenia ....................................................................  91 
Transcriptional Regulation of the α7 Nicotinic Receptor...............................  97 
BIBLIOGRAPHY .....................................................................................................  101 
VITA  ......................................................................................................................  115 
 
 
 9 
LIST OF TABLES 
 Page 
1.  Percent of Discharged Patients Diagnosed with Schizophrenia ........................  13 
2.  Nicotinic Receptors ...........................................................................................  19 
3.  Sequence Homology of the α7 Nicotinic Receptor.............................................  42 
4.  Transcription Factors Known for the AChRα7 Receptor ....................................  44 
5.  Clinical characteristics .......................................................................................  62 
6.  Functional Half-CRE Elements ..........................................................................  74 
 
 10 
LIST OF FIGURES 
 Page 
1.   Representation of Nicotinic Receptor Channels................................................  18 
2.   Two Groups of Nicotinic Receptors...................................................................  19 
3.   Division within receptor families usually occurs based on ligand affinity...........  21 
4.   P50 Inhibition Pharmacological Responses......................................................  24 
5.   Four Factors Implicating the α7 Receptor in the Neuropathology of  
      Schizophrenia ...................................................................................................  26 
6.   Potential effects Acetylcholine has on Dopamine and Glutamate Release.......  30 
7.   Potential Auto-antibody Effects on the Neuron .................................................  34 
8.   Neurotransmitters Affected by Diminished α7 Receptor Expression.................  36 
9.   The α7 Nicotinic Receptor Protein ....................................................................  41 
10.  Antibodies to the nAChRα7 Receptor Found in Schizophrenia vs. Healthy  
       Controls….. ......................................................................................................  60 
11.  The Linear Comparison of Antibody Titer to Age in the Patient Population  
       Compared to Controls......................................................................................  61 
12.  Potential Regulation of nAChRα7 Expression by CREB..................................  73 
13.  EMSA Assays Illustrating CREB Binding to the CHRNA7 Promoter................  75 
14.  The Invitro and Invivo Identification of CREB Protein Bound to the CHRNA7  
       CRE Half-element in the Promoter Region ......................................................  78 
15.  Functionality of the CRE Half-element is Evaluated by Luciferase Reporter  
      Gene Assays.....................................................................................................  80 
16.  Dominant-Negative CREB Mutants Affect α7 Transcription.............................  81 
17.  Invivo Functional Analysis of the α7 Subunit Promoter utilizing Luciferase  
       Reporter Gene Assay ......................................................................................  82 
18.  Possible CREB Pathways Associated with α7 Expression ..............................  86 
19.  Recombinant α7 Protein ..................................................................................  91 
 11 
20.  ELISA Assay utilized to Determine Sera IgG Levels Against α7 Receptor in  
       Schizophrenics.................................................................................................  92 
21.  Antibody Specificity to Recombinant α7 Receptor Amino Acid Sequence .......  95 
22.  SHEP1 and SHEP1-pCEPa7 Cells in α7 Autoantibody Evaluation..................  96 
23.  Potential Interactions Between CREB Isomers and the nAChRα7 Promoter...  98 
 12 
CHAPTER 1 
INTRODUCTION 
 The search for biological basis of schizophrenia has filled many scientists 
with more questions than answers at the end of their studies.  A prominent figure 
in the initial move from the psychoanalytical dogma that dominated early 
schizophrenia research, Dr. Fred Plum, referred to the disease as the graveyard 
of the neuroscientist.  It is the inability to make specific molecular distinctions in a 
symptomatically indistinct disorder that has left many demanding more 
information1.  Recent scientific discoveries, particularly in the human genome, 
are finally contributing to the identification of unique biological factors and their 
relationships that seemingly contribute to the neuropathophysiology of 
schizophrenia.  It is the purpose of the present study to look at a particular 
molecule, the α7 subunit of the nicotinic receptor, and elucidate how it may 
participate in the disease.   There are two distinctly different avenues explored in 
this investigation regarding the receptor.  The first avenue examines protein 
interactions that may inhibit proper functioning of the receptor.  The second 
avenue examines the transcriptional regulation of the receptor subunit, which is 
currently uncharacterized.  
 
Background 
Schizophrenia affects up to 1% of the world’s population.  In the United 
States, the estimated prevalence of schizophrenia is 1 in 125 individuals.  To put 
this in better perspective, a city consisting of one million people will have at least 
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8000 suffering from schizophrenia.  According to a recent report on Medscape 
Today, Dr. Natalya Weber of the Walter Reed Army Institute released the 
following information, located in Table 1, at the American Psychiatric 
Association’s annual meeting that used analyses obtained from 5.7 million US 
National Hospital Discharge Surveys (abstract NR4-073, May 5, 2008): 
 
Table 1.  Percent of discharged patients diagnosed with schizophrenia.  This 
table illustrates the statistics associated with individuals who had a diagnosis of 
schizophrenia upon hospital release. 
 
Demographic  Rate of Schizophrenia 
Schizophrenia overall 1.0% 
Males 1.3% 
Females 0.8% 
African American 1.8% 
Caucasian 0.9% 
Other race 1.0 % 
US region 
North 
Midwest 
South/West 
 
1.5% 
1.0 % 
0.8% 
 
Also, Dr. Weber’s group examined the prior 24 years and discovered the average 
hospital stay for someone with schizophrenia is twice as long as the general 
population at 12.5 days.   
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Hospitalization of schizophrenic patients is just one example of the 
debilitating nature of the disease that contributes to a heavy financial burden to 
not only the individual but to the public as well.  Other examples are initially lost 
wages or services, disability payments, costly therapeutic management, and 
eventual long-term care.  In 2002, it was estimated the cost of schizophrenia 
exceeded $62 billion dollars that year, with almost half going to direct care cost 2.  
Schizophrenia is generally regarded as the most expensive disorder worldwide.   
Many argue the current amount of research dollars designated for schizophrenia 
does not match the importance the disease occupies financially in everyday life.   
With schizophrenia’s effects immediately felt by a large number of people, it is 
extremely important for current research to identify any biological components 
that could contribute to a disease with such an ill-fated patient prognosis. 
 
Epidemiology 
 The epidemiology behind schizophrenia is most interesting.  Men 
experience their first psychotic episode around 25 years of age, while women are 
closer to 30 years of age.  More literature regarding early onset schizophrenia is 
becoming available, with most researchers citing lack of diagnosing criteria 
regarding childhood symptoms as the main culprit in correctly assessing 
schizophrenia.  But it is generally accepted that disease manifestation occurs in 
early adulthood.  A common misconception is that the disease affects men and 
women equally.  However, a recent meta-analysis assessed 31 independent 
review articles and found a significant difference of 1.4 males for every female3.  
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The disease also varies from country to country, illustrating strong genetic 
influences3.  Family history, genes, stressful life events, birth complications, 
infection, influenza, autoimmunity, ethnicity, and cannabis use are some of the 
more well-known risk factors associated with schizophrenia [as reviewed most 
recently by Messias4].  Along with genetic markers, another factor of particular 
interest to this study is the relationship to influenza.  An individual whose mother 
experienced influenza during the second trimester of pregnancy appear to be at 
a 2-3 times higher risk for developing schizophrenia than the general 
population5,6.  Season of birth is also considered a slight risk factor, with winter 
babies illustrating a higher rate of the disease7.   This could be explained by the 
occurrence of the second trimester when influenza risk is the greatest8.  It is quite 
possible neuro-developmental dysfunctions may have happened during this 
exposure implicating specific biological mechanisms, in particular neuronal 
signaling pathways and immune system functions.  These alterations could 
contribute to the unique manifestation of the disease in early adulthood when the 
deficient biological mechanisms could no longer be compensated for.  The 
fascinating epidemiology behind the disease illustrates the participation of 
specific biological factors or their distinct relationships that have yet to be 
identified in schizophrenia. 
 
Diagnosis 
 Understanding the clinical characteristics that attempt to distinguish 
schizophrenia from other closely related mental disorders is important in the 
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ability to form specific biological connections.  The clinical identification of 
schizophrenia is not all that different than it was 50 years ago.  A patient is 
interviewed by a clinician, who through the patient’s responses begins to dissect 
the core issues and makes a clinical diagnosis.  It is not all that uncommon for 
the initial diagnosis to be changed, due to the complex nature of subjectively 
identifying mental disorders.  A clinical diagnosis of schizophrenia involves the 
manifestation of negative and positive symptoms, even in some cases alternating 
between the two.  Negative symptoms involve a loss of the ability to perform 
everyday functions.  Affective flattening, one of the more common symptoms of 
schizophrenia, is a reduction in responsiveness by the individual, noted by poor 
eye contact and reduced facial expressions.  Alogia is a lack of speech, 
characterized by the inability, not the unwillingness, to speak.  Avolition is the 
inability to express interest in any persistent activity.  Positive symptoms are the 
exacerbation or alteration in normal functions including: delusions, disorganized 
thinking, grossly disorganized behavior, catatonic motor behaviors, and sensory 
hallucinations, including auditory hallucinations that are by far the most common 
symptom of schizophrenia.   According to the DSM-IV, a schizophrenia diagnosis 
involves the following criteria.  First, two of the five symptoms must occur for the 
majority of a one-month period, unless delusions are characterized as bizarre, 
then this may be sufficient alone.  Second, any functional area, such as work, 
home, or education, must be moderately to severely impaired.  Last, the signs of 
general unusual behavior must be evident for at least six months.  Stahl adheres 
to a more stringent diagnosis, including cognitive, aggressive, and depressive 
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symptoms, calling for a separate assessment of these areas during patient 
evaluation (Stahl, 2nd edition). 
 Paranoid, Disorganized, Catatonic, Undifferentiated, and Residual are all 
specific subsets under the general heading of schizophrenia, with each 
possessing individual characteristics that warrant a more distinct identification of 
the disease.  One year following initial diagnosis, patients fall into one of the 
following divisions:  episodic with inter-episodic residual or negative symptoms, 
episodic with no inter-episodic symptoms, single episode in partial remission, 
single episode in full remission, or unspecified pattern (DSM-IV, 4th edition).  This 
multifaceted diagnosing criteria illustrates the complexity in distinguishing mental 
disorders in general.  The pathophysiology involved in the etiology of 
schizophrenia is likely to be similarly complex.       
 
The Purpose of the α7 Subunit of the Nicotinic Receptor in Schizophrenia 
 The nicotinic receptor α7 subunit (nAChRα7) is a molecule of particular 
interest in schizophrenia.  Nicotinic receptors are ligand-gated ion channels that 
participate in neurotransmission and cell signaling within the body.  Nicotinic 
receptor ion channels form from the intertwining of five identical or different 
receptor subunits (Figure 1).  The subunits consist of α2 through α10 and β2 
through β4.  The α-subunits carry the specific components involved in specific 
acetylcholine ligand binding, while the β-subunits contain complementary 
components that do not possess ligand binding capability.   The known 
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pentameric channels formed from nicotinic subunits are identified in the brain as 
shown in Table 1.2.  The α7 subunit is not only confined to CNS expression, 
  
 
 
 
 
 
 
 
 
 
Figure 1.  Representation of nicotinic receptor channels.  A homomeric nicotinic 
receptor ion channel consists of five identical α subunits that contain five 
acetylcholine binding sites, denoted by stars.  A heteromeric or multimeric ion 
channel consist of acetylcholine binding α units and beta complement units in 
various configurations, shown here is an (α4β2) receptor.   
α7
α7
α7 
α7
α7
α4
α4
β2
β2
β2
Homomeric Heteromeric
OR
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Table 2. Nicotinic receptors.  This a list of the functional nicotinic pentameric 
channels formed from receptor subunits and their location in the brain.  Gotti and 
Clementi, 2006. 
 
Hippocampus α7, α4β2, α4β2α5, α3β4 
Medial habenula α7, α4β2, α3β4, α3β3β4 
Pineal gland α7, α3β4 
Cerebellum α7, α4β2, α3β4, α3β2 
Locus Coeruleus α3β4, α6β2β3 
Spinal cord α7, α4β2, α3β2  
Raphe nuclei α4β2 
Interpeduncular n. α7, α4β2, α2β2, α3β3β4 
Substantia nigra, VTA α7, α4β2, α4β2α5, α3β4, α6β2β3 
Thalamus α4β2 
Hypothalamus α7, α4β2 
Amygdala α7, α4β2 
Striatum α4β2, α4β2α5, α6β2β3, α6α4β2β3 
Olfactory Bulb α7, α4β2 
Cortex α7, α4β2, α4β2α5 
 
 
it has been found expressed in blood leukocytes and endothelial cells 9-11.  In the 
immune system, it participates directly in cell signaling events that result in 
activation of the anti-inflammatory pathway, while suppressing the pro-
inflammatory pathway12.  
 
 
 
 
 
Figure 2.  Two groups of nicotinic receptors.   The initial separation of the 
nicotinic receptors was based on their functional ion channel properties.  The α7 
receptor functions as a calcium channel, while the other receptors, for example 
α4β2, function as sodium and potassium channels.   
 
Nicotinic receptors 
Ca2+ channel
ex. α7
Na+, K+ channel
ex. α4β2
 
 20 
The α7 nicotinic receptor distinguishes itself from the other nicotinic 
receptors in two important areas, function and pharmacology.  The receptors 
formed from the α7 subunits participate in cell signaling as ion channels that 
result in a cellular increase in the permeability to calcium, differing from the other 
known nicotinic receptor ion channels that increase sodium and potassium 
permeability (Figure 2).  The nicotinic receptor family directly participates in 
neurotransmission, and this functional difference is meant to distinguish the 
modulation of the different neurotransmitters.  The α7 subunit has been thought 
to be pharmacologically distinct from the other subunits due to the ability to bind 
bungarotoxin, a toxin found in cobra venom (Figure 3).  This was how initial 
classification of nicotinic receptor subunits was divided, those receptors that 
exhibited bungarotoxin binding and those that did not.  However, recent evidence 
has shown that bungarotoxin has the ability to bind the α8 (found only in chick 
retina to date), α9, and α10 subunits (both subunits found in human pituitary 
gland and inner ear)13.  Also, the receptor does not respond to the antagonist 
mecamylamine, which blocks the other known nicotinic receptors14.   
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Figure 3.  Division within receptor families usually occurs based on ligand affinity.  
Ligand binding assays utilizing nicotine affinity initially divided the nicotinic 
receptors into separate categories: low, moderate (Mod) and high.  Bungarotoxin 
affinity (αBTX) exhibited only by the α7 nicotinic receptors receptors was used to 
further distinguish this particular group of receptors.   
 
A special point of interest is the lack of complete information regarding the 
nicotinic receptor family.  It is noted in the latest review by Dr. Clementi (one of 
the pioneers in nicotinic receptor research) that the list of identified functional 
receptor ion channels in the human brain is far from complete15.  Affirming this 
statement are reports that the α7 subunit may exist not only in homomeric ion 
channels of five identical subunits but also in α7 multimeric ion channels as well.  
Although this idea is not generally accepted, there is a moderate amount of 
literature to support the possibility--especially in the chick retina and rat 
hippocampal interneurons where functional α7 receptors behave 
Nicotinic 
receptors
Low Mod
αBTX bind
α7 receptors
High
Nicotine affinity
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pharmacologically different from homomeric counterparts16-18.  This illustrates 
that technical issues must be taken into account when precisely identifying the α7 
receptor from other nicotinic receptors in current molecular investigations.     
Many of the identified nicotinic receptor subunits have been implicated in 
the neuropathology of a variety of diseases.  The α4β2 receptor has altered 
expression in Alzheimer’s disease19.  The α6, β2, α7, and α4 subunits are all 
being evaluated in association with Parkinson’s disease20,21.  Nicotine has been 
reported to be a mood stabilizer in depression and to increase attention in 
ADHD22,23.  Four initial findings in the schizophrenic patient population 
immediately implicate the nAChRα7 as important molecules involved in the 
neuropathology of the disease24.   
 One of the first factors noticed associating nicotinic receptors with 
schizophrenia was the high incidence of smoking in the patient population.   More 
than 90% of the schizophrenic patient population use nicotine in some form25.  
This implicates the nicotinic receptor family immediately.  All the known functional 
nicotinic receptors are divided based on their selective ligand affinity to nicotine 
in combination with other selective agents, such as bungarotoxin as discussed 
previously.  Nicotine binds the homomeric α7 receptor with low affinity; however, 
with chronic nicotine treatment an up-regulation of the functional α7 receptors 
has been shown in neuronal cells26.   Schizophrenic patients could potentially be 
self-medicating with nicotine, although the molecular basis has never been 
completely identified due to the relatively poor knowledge of neuronal 
mechanisms in general of the nicotinic receptors. 
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 Another factor involves the α7 receptor’s relationship to abnormal auditory 
gating, one of the few physiological alterations found in schizophrenia.   
Abnormal auditory gating is one of the few measurable phenotypic traits that 
takes advantage of this abnormal reaction to stimulus by comparing subject 
responses in corresponding stimuli.  This physiological response in 
schizophrenia is called the P50 abnormal gating phenomenon.  The P50 wave is 
an electrically positive evoked potential that occurs 50 ms following a response to 
paired auditory stimulus.  The measurement is conducted using 
electroencephalogram readings of the P50 wave amplitudes.  The subject is 
administered an auditory stimulus, the initial amplitude measured, then 
immediately exposed to a second auditory stimulus, and the P50 amplitude is 
measured 50 ms later.  The ratio of the initial potential and the P50 response is 
evaluated, which is referred to as P50 inhibition27.  In normal individuals, the ratio 
is well below 0.5, but in the schizophrenic population the ratio is above the 0.5 
ratio.  This means wave amplitudes are becoming closer in size supporting a 
patient response to all environmental stimuli instead of effectively focusing on a 
single stimulus or being able to “filter” distractive environmental sounds 28.  The 
biological basis of proper P50 inhibition is directly linked to neurons in the 
hippocampal region.  Only the α7 receptor antagonist, α-bungarotoxin, was able 
to disrupt P50 inhibition, while antagonists for other nicotinic receptors had no 
effect29.  Nicotine has a low affinity for the α7 receptor but was sufficient to 
normalize the P50 inhibition in schizophrenia without interference from 
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mecamylamine, a known antagonist for all nicotinic receptors except the α7 
receptor, as summarized in Figure 4.14,29    
 
 
 
 
 
 
 
 
Figure 4.  P50 inhibition pharmacological responses.  P50 inhibition is diminished 
after lesions to the hippocampus in animal models, but restored with subsequent 
nicotine treatment.  Treatment with α-bungarotoxin, an α7 specific antagonist, 
diminishes P50 inhibition, while treatment with mecamylamine, which blocks all 
functional nicotinic receptors but α7 receptors, does not result in loss of P50 
inhibition24.   
 
 A third factor implicates the α7 subunit through genetic linkage studies that 
evaluated genotypes in the families of schizophrenic patients with deficient 
auditory gating.   Dr. Freedman’s group evaluated nine schizophrenic patients 
and their first order relatives, showing the P50 auditory gating deficit is 
genetically linked to α7 nicotinic receptor locus on chromosome 15q1424.   There 
were several studies following this initial finding that also found α7 nicotinic 
receptor genetic linkage to specific populations, including those of African 
American and Northern European American decent30,31.  A meta-analysis 
conducted in 2002 evaluated 18 separate studies to find a significant correlation 
P50 inhibition
Hippocampal lesions
Nicotine
P50 inhibition
P50 inhibition
α-bungarotoxin Mecamalymine
P50 inhibition
P50 inhibition
 
 25 
between the α7 locus and schizophrenia32.  It is worth pointing out that several 
investigations involving Asian lineage have not found genetic linkage of the 
receptor to schizophrenia33,34.   The genetic linkage of the α7 subunit to certain 
cultural populations stresses the importance of genetic susceptibility that may put 
someone at risk for developing the disease.   However, schizophrenia has 
always been considered a multifactorial illness that involves the interactions 
between genetic components and environmental contributions that may 
eventually evolve into disease state for some patients.     
A fourth factor involves α7 receptor expression in schizophrenia.  Ligand 
binding assays using α-bungarotoxin, an α7 receptor antagonist, in autopsy 
tissue suggest the amount of this ion channel is significantly reduced in the 
brains of schizophrenics when compared to controls, particularly in the frontal 
cortex and hippocampal regions35.  Messenger RNA studies are much less clear, 
with conflicting reports regarding the actual number of α7 subunit transcripts in 
schizophrenics36-38.  However, a recent report introduced novel splice variants of 
the α7 subunit mRNA and the changes in expression regarding each variant in 
different areas of the brain in schizophrenia39.  Although the function of these α7 
transcription variants is unknown, abnormal transcription levels of them in the 
brains of schizophrenics may contribute to deviant receptor expression or 
functional alterations in channel activity.  Taken together, these four factors 
suggest the α7 receptor may have a role in schizophrenia (Figure 5).  
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Figure 5.  Four factors implicating the α7 receptor in the neuropathology of 
Schizophrenia.  Smoking, the P50 inhibition (ratio of the measurements of P50 
amplitudes), genetic linkage to chromosome 15 locus 14, and altered receptor 
expression link the α7 receptor to the biological basis of schizophrenia.  
 
Etiological Hypothesis of Schizophrenia 
 The complete biological basis of schizophrenia has remained elusive 
through the years.  The advent of better molecular tools has resulted in more 
information.  Schizophrenia does not appear to be the result of one particular 
causative factor, but rather, it is the result of complex relationships between a 
variety of biological interactions, some of which may involve the α7 nicotinic 
receptor.   Briefly discussed below are several of the more informative etiologies 
that contribute to the neuropathophysiology of schizophrenia and their general 
relationship to the nAChRα7.   
Smoking
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Dysregulated Immune System 
Schizophrenia was initially thought to be an autoimmune disorder based 
on the similarities shared with onset and progression of other autoimmune 
diseases.  They both manifest into disease later in teens or early adulthood, 
possibly triggered by an outside contributing factor such as a virus.  Autoimmune 
disorders and schizophrenia both tend to have periods where the disease is 
worse at certain times intermingled with periods of remission.  Autoimmunity 
results from a person’s immune system to produce an abnormal response to his 
or her own tissue.  Schizophrenic patients exhibit a dysregulated immune 
response as well.  More specifically, there are increased cytokine levels, 
particularly IL-6 and IL-2 found in schizophrenics40.  According to another study, 
there is a 45% increase in the development of schizophrenia if any other 
autoimmune disease is noted in family history41.  It has been found abnormal T-
cell activity can contribute to the cognitive deficiencies noted in schizophrenia42.  
Also, immunosuppressive therapy along with anti-psychotic treatment 
significantly improves disease prognosis43.  It is hypothesized that a portion of 
patients with schizophrenia may have autoantibodies for specific proteins 
accounting for the dysregulated immune system observed, such that 
autoimmunity contributes to the development of this disorder in a portion of the 
patient population.  
The function of the α7 nicotinic receptor in inflammation has just recently 
become of interest.  For many years, the receptor family was thought to be 
located only in the CNS.  Recently, the α7 receptor was identified on leukocytes 
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and found to participate directly in activation of the anti-inflammatory pathway, 
while suppressing the pro-inflammatory pathway, as reviewed most recently by 
Gallowhitch-Puerta12.  These findings stimulated a closer look at inflammation in 
the CNS associated with psychiatric illness.  The CNS mononuclear phagocytes, 
called microglia, serve as the primary cell population for the brain’s inflammatory 
response.  It was found that microglia activation was regulated by α7 receptors44.  
The α7 receptor is essential in the proper cell signaling events in the CNS as well 
as peripheral immunity.  An alteration in receptor expression or function could 
result in the dysregulated immune response displayed in schizophrenia.   
 
Dopaminergic Hypothesis 
 The dopaminergic pathway probably has the longest history of association 
with schizophrenia.  In fact, dopamine activity has been isolated to particular 
pathways that could specifically contribute to the symptoms exhibited by 
schizophrenics.  It has long been shown that stimulants that increase dopamine 
receptor activation can produce or worsen psychotic episodes45.  The 
relationship was further defined in schizophrenia, where an increase in dopamine 
through the mesolimbic pathway exacerbates positive symptoms, but if dopamine 
is decreased positive symptoms are diminished46-48.  However, in the 
mesocortical pathway dopamine deficiency results in an exaggeration of negative 
symptoms49.  Antipsychotic-induced loss of dopamine activity in the nigrostrial 
pathway results in movement deficits exhibited by schizophrenics50,51.   The 
precise role of dopamine in schizophrenia has yet to be thoroughly elucidated, 
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but the involvement of the neurotransmitter’s pathways in the illness has much 
support52.   Currently, the most effective pharmacological treatment in 
schizophrenia is dopamine receptor antagonists.  
 The relationship between nicotinic receptors and dopamine release is far 
from complete, but there are elements that can be stated with confidence.  The 
α4β2 heteromeric nicotinic receptor responds to acetylcholine to participate 
directly in the release of dopamine throughout the brain.  Glutamate, which 
responds to α7 receptor activation, is thought to facilitate dopamine release as 
well 53.  These primary and secondary associations with dopamine establish the 
importance of nicotinic receptors as a whole in dopaminergic pathways (Figure 
6).   Any disruption of proper nicotinic receptor function will have an effect on 
dopamine modulation that could result in the symptoms associated with 
schizophrenia that were mentioned in the previous paragraph.  
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Figure 6.  Potential effects Acetylcholine (ACh) has on Dopamine (DA) and 
Glutamate (Glu) Release.  The neurotransmitter, ACh, directly facilitates the 
release of both glutamate and dopamine but also participates in dopamine 
release indirectly through glutamate binding to dopamine neurons (adapted from 
Wonnacott)53. 
 
 
Cellular Neurodegeneration 
 
Those suffering from schizophrenia demonstrate a progressive worsening 
throughout their lifetime if they do not enter remission.  Even before diagnosis, 
there is a gradual progression toward psychosis that has a measurable level of 
reliability that could be used to predict those individuals who may develop 
schizophrenia54.  This would seem to reinforce a neurodegenerative basis behind 
the disease.  Inefficient neurotransmission resulting in reduced neuroprotection 
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has been proposed to explain the gradual downhill progression exhibited by 
schizophrenics (Stahl, 2nd edition).  The coordinated actions of inhibitory and 
excitatory amino acids are of particular interest in this area.  Glutamate release is 
thought to be under the direct control of presynaptic α7 nicotinic receptor in the 
cerebrum and cerebellum, while the hippocampus neurotransmitter release is 
under the control of complex secondary interactions with the receptor that may 
involve other neurotransmitters 13,55,56.  Activation of the receptor results in the 
release of calcium stores within glutaminergic neurons facilitating 
neurotransmitter release 57.  The release of the inhibitory neurotransmitter, γ-
aminobutyric acid (GABA) in the hippocampus falls under the control of the α7 
nicotinic receptors58.  Dysregulation of GABA release has been associated with 
schizophrenia, supported by a loss of a GABAergic interneurons59,60.  Loss in α7 
receptor function or regulation disrupts precise neurotransmitter communication 
that could result in molecular neurodegeneration in specific areas of the brain 
explaining the clinical progression of schizophrenia.   
 
Environmental Factors      
Environmental triggers dominated early etiological studies of the disease, 
while molecular methods emerged with scientific evidence to support a biological 
basis.  Discussed below are epidemiological findings that support an intertwining 
of both biological and environmental causes in the etiology of schizophrenia.  
Strong substantial evidence of an non-genetic influence is exhibited through the 
concordance level between monozygotic twins, which was found in early studies 
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to be around 28%61.   Stressful life events have been postulated to contribute to 
the beginning of schizophrenia or to episodic relapses.  Walker and coworkers 
reviewed a stress-sensitive pathway, the hypothalmic pituitary adrenal axis 
(HPA), and found activation of the stress hormone cortisol results in an 
exacerbation of psychotic symptoms in schizophrenia animal models62.  Maternal 
exposure to toxins or micoorganisms during gestation could be another 
environmental contribution resulting in the neuronal deficits manifesting in 
schizophrenia.  A study in a Netherland population during the Germany invasion 
of 1940 revealed that offspring of women pregnant at this time exhibited higher 
incidences of the disease63.   The specific role of the α7 receptor in the previous 
examples is unknown.  However, studies of fluoride exposure with SHSY5Y 
neuronal cells and animal models resulted in a decline of expressed α7 nicotinic 
receptors64,65.  This is direct evidence that toxin exposure could significantly 
impact the appropriate function of the α7 nicotinic receptor.  Taken together, this 
information suggests that environmental influences on specific molecular 
mechanisms could be actively contributing to the manifestation or worsening of 
schizophrenia through particular signaling molecules, for example the α7 
receptors.   
 
Genetic Contributions  
 Although schizophrenia has been demonstrated as a multifactoral illness 
with a plethora of environmental risk factors, the genetic susceptibility of 
schizophrenia cannot be overlooked.   Dominating the current research literature 
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in schizophrenia are genetic linkage studies that have identified possible 
candidate genes involved in the disease.  Potential genes are examined through 
a variety of methods, including mass ChIP arrays and single nucleotide 
polymorphism identification.  These types of studies have introduced many 
possible targets that may contribute to the symptoms shown by schizophrenic 
patients.  It has been shown that nearly every chromosome exhibited some 
degree of genetic linkage to schizophrenia, suggesting a high degree of 
complexity in the disease66.  Meta-analyses by Lewis et al. looked at 
systematically prioritizing the more heavily studied chromosomal regions relating 
to schizophrenia67.  There are many distinct genes that have been identified with 
a statistically significant association with schizophrenia.  However, their 
participation in the pathogenesis of schizophrenia is only now being investigated. 
The α7 nicotinic receptor subunit is one of those target genes that meets both a 
statistical criterion and a physiological deficit that can be associated with the 
disease.   
Specific Aims 
The α7 receptor has emerged as a molecule highly implicated in the 
neuropathophysiology of schizophrenia.  The receptor displays potential 
involvement with the dopaminergic, neurodegenerative, and autoimmune 
etiological theories of schizophrenia as well as displays direct genetic linkage to 
the disease.  Schizophrenia has always been considered a multiplex disease that 
could have a plethora of different causative factors.  It may be that the α7 
receptor could be the part of the puzzle that clarifies otherwise poorly understood 
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neuronal relationships found in the disease.  It is the purpose of the present 
studies to further characterize the role of the receptor in schizophrenia through 
two entirely different avenues.  Improper function or amount of the α7 receptor 
could contribute to the biological relevance of the receptor in schizophrenia.  .  
The function of the α7 receptor is extremely important in proper neuronal 
processes as discussed previously.   Disrupted neurotransmission is likely at the 
center of the neuropathology of schizophrenia.  When combined with the putative  
immune dysregulation noted in the neuropathology of the disease, it is 
conceivable that the schizophrenic may be producing its own nAChR ligand, for 
example in the form of an antibody.  The neurotransmitter and immune 
deficiencies could be explained by the presence of an auto-antibody that 
disrupted proper α7 receptor functioning.   The ligand-gated ion channel 
properties of the α7 receptor that delicately control cellular communication could 
be subject to interference through an auto-antibody binding event (Figure 7).  
This binding  
 
 
 
 
     
 
Figure 7.  Potential auto-antibody effects on the neuron.  The effects of an 
antibody specific for the α7 receptor could be antagonist-like (top nAChRα7 
receptor), where the channel would be blocked, or agonist-like, where the 
channel would be found in a constant open state (bottom nAChRα7 receptor).     
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could involve two potential outcomes.   The antibody could block proper receptor 
function, resulting in an antagonist-like event.  Or the antibody could act as a 
positive allosteric modulator, where the channel would be in the open 
conformation.  As stated previously, the exact role of the α7 receptor in neuronal 
processes is poorly understood, so to state the outcome of antibody binding 
events on receptor function is speculation at this point but will be examined 
further in Chapter Five. 
 The second avenue explored in these studies examines the regulatory 
mechanisms that control the endogenous amount of functional receptor.  The 
events that control α7 receptor subunit expression are not well known.  In fact, 
only one transcription factor in the human α7 subunit has been characterized to 
date.  Bungarotoxin binding assays reveal a significantly lower amount of 
functional α7 receptor in the brains of schizophrenics 35.  Also reported are lower 
expression levels of receptor subunit mRNA expressed in lymphocytes38.  
Diminished receptor expression would directly influence proper neuronal 
functioning that would be dependent on the cell type and location in the human 
brain.  This lack of translational product could be due to inefficient transcription of 
the α7 subunit.  Subunit concentration could directly affect cellular events that 
eventually conclude in the formation of functional homomeric or heteromeric α7 
receptors.   Without significant amounts of α7 receptor, the presynaptic signaling 
events that directly control glutamate and GABA release would be diminished.  
Also, the α7 control of dopamine via secondary signaling from glutamate would 
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be compromised as well.   However, the role of α7 receptors specifically in 
dopamine transmission is unknown at this time and the effects it may have could 
not be stated confidently, but the complexity of the crosstalk between 
neurotransmitters is well-known.   Consequences from the loss of efficient 
neurotransmission involving one transmitter would have a ripple effect on many 
separate neurotransmission events (Figure 8).  This ability to communicate 
between neurons could be severely compromised by the inefficient transcription 
of one receptor subunit that resulted in a loss of functional receptor.   
 
 
 
 
 
  
  
 
 
 
 
 
Figure 8.  Neurotransmitters affected by diminished α7 receptor expression.  The 
neurotransmitters glutamate and γ-aminobutyric acid (GABA) would be directly 
affected by decreased α7 receptor function or expression.  However, the ripple 
effect on overall neurotransmission could disrupt other events involving 
dopamine (DA), acetylcholine (ACh), norepinephrine (NE), and serotonin (5-HT) 
modulation.    
 
Therefore, the specific aims of this study were:  1) to develop the 
recombinant production of the α7 nicotinic receptor in a variety of expression 
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systems and to determine the integrity of the product; 2) to determine if there are 
auto-antibodies to the nAChRα7 by analyzing schizophrenic patient and control 
blood serum; and 3) to functionally characterize the cyclic AMP response 
element in the promoter region of the α7 subunit gene and identify any 
involvement in the transcriptional regulation of the receptor.  
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CHAPTER 2   
MOLECULAR ADVANCES AND DISCOVERIES REGARDING THE α7 
SUBUNIT OF THE NICOTINIC RECEPTOR  
 
Background 
Nicotinic receptors (nAChR) belong to a large family of ligand-gated ion 
channels responsible for cellular communication.   These receptors are 
composed of five subunits that consist of either homomeric or heteromeric 
combination of alpha (α) or beta (β) subunits.  Currently, the known subunits are 
α2 through α10 and β2 through β4.  The acetylcholine nicotinic α7 subunit 
(nAChRα7) receptor is composed of five identical α7 subunits that form a ligand-
gated ion channel.  The α7 receptor was first discovered based on the ability to 
bind to α-bungarotoxin, a deadly snake toxin that attacks the central nervous 
system of victims. 
 
History and Location of the α7 Nicotinic Receptor 
The α7 nicotinic receptor was originally thought to be expressed only as a 
neuronal receptor in the CNS.  The regions in the brain found to have high 
expression levels are the nucleus reticularis of the thalamus, the lateral and 
medial geniculate bodies, the basilar pontine nucleus, the horizontal limb of the 
diagonal band of Broca, the nucleus basalis of Meynert, and the inferior olivary 
nucleus68.  More recently, the α7 nicotinic receptor has been identified in 
peripheral tissues such as endothelial cells (ECs), bronchial epithelial cells, skin 
keratinocytes, and vascular smooth muscle9-11,69.  The tissue variation of the 
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nAChRα7 receptor would indicate the intense regulation the gene is under in 
order to achieve such distinct expression patterns68.    
 The role of the receptor in each tissue is increasingly becoming clear.  In 
the CNS, the receptor is responsible for participating in signal transduction at a 
post-synaptic and pre-synaptic level crucial to early developmental70.  The 
nAChRα7 receptor appears to work in four distinct manners in the CNS:  
postsynaptic fast transmission, axonal transmission, increase in intracellular 
Ca2+, and opening of voltage-gated channels71.  The receptor also exhibits a high 
permeability to Ca2+, which could result in activation of secondary messenger 
systems or cell death72,73.  In the immune response, nAChRα7 has not only been 
shown to participate in cell proliferation but more specifically in the support of B-
lymphocyte survival through IgM and CD40 expression74.   The nAChRα7 
receptors found in skin keratinocytes are responsible for aiding in cell cycle 
regulation and participation in setting up the epithelium barrier75.    
 
Pathophysiology of the nAChRα7 Receptor 
The pathophysiology of the nAChRα7 receptor has been scrutinized 
heavily in the past few years.  It is increasingly becoming a more popular 
candidate gene in mental disorders such as schizophrenia.  The strong 
correlation between nicotine usage and schizophrenia lends support to the 
further examination of the relationship between the nicotinic receptor and 
disease.  The inability to filter background stimuli known as the P50 gating deficit 
and the insufficiency in following visual stimuli are measurable traits in 
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schizophrenia corrected by nicotine administration76,77.  Genetic linkage to 
schizophrenia involving the CHRNA7 chromosome has been debatable, but 
mounting evidence concludes it is a viable candidate78-82.  The nAChRα7 
receptor expression has been shown to be decreased in neuronal cells of 
schizophrenics, as well in peripheral blood cells35,83.    Age-related diseases such 
as Alzheimer’s (AD) and Parkinson’s (PD) have examined altered expression 
levels of the receptor, with AD demonstrating a detailed involvement between the 
receptor and β-amyloid accumulation84-86.   Major depressive disorder and bipolar 
disease research is beginning to characterize nAChRα7 involvement as well36,87.  
With the emerging notoriety the nAChRα7 receptor is gaining, this review 
attempts to look at the molecular information and recombinant tools available to 
study the receptor.   
 
Molecular Biology of the nAChRα7 Receptor 
 
Protein Structure of the nAChRα7 Receptor 
Each α7 subunit of the nicotinic receptor, illustrated in Figure 9, consists of 
a 502 amino acid molecule with four trans-membrane spanning regions, a large 
extracellular amino terminal domain, and an intracellular loop between 
membrane three and membrane four88.   
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Figure 9.  The α7 nicotinic receptor protein.  This figure is a representation of the 
four membrane spanning regions and dual cysteine bridges found in the amino 
portion of the receptor.  Each ion channel consists of five identical receptors, with 
ligand-binding occurring in the amino portion of the receptor.   
 
Extremely selective ligand binding occurs at the extracellular amino terminal of 
the receptor89.  It could be a single amino acid between membrane regions two 
and three is responsible for the gating response that occurs upon ligand binding, 
more specifically interactions with N-terminal cysteine loops could be directly 
responsible for communicating these changes90,91.  The presence of highly 
conserved dual cysteine (C150 and C164) residues in the nAChRα7 extracellular 
region are necessary to form properly assembled receptors91.  The nAChRα7 
amino acid formation can vary greatly between species (Table 3).  Within 
species, the crucial ligand-gated extracellular portion and pore lining region 
NH3
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M1 aa231-aa254  M3 aa293-aa315 
M2 aa261-aa283  M4 aa472-aa494 
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exhibit sequence similarity throughout the mammalian species.  However, once 
one moves to insects, sequence sharing becomes much less evident, especially 
in the extracellular and intracellular signaling domains.   
Table 3.  Sequence homology of the α7 nicotinic receptor.  This table illustrates 
the sequence homology of the α7 nicotinic receptor between species and within 
specie, when compared to the human nAChRα7 receptor.  
 
Species   Gi accession number  % identities 
Cow     gi|27806239   95% 
Mouse    gi|156766082  93% 
Rat     gi|144922602  93% 
Chick     gi|45383758   90% 
Zebrafish    gi|41054962   78% 
Cat flea    gi|78369196   61% 
Red flour beetle   gi|157783852  49% 
Tobacco budworm subunit-2 gi|4895007   49% 
Tobacco budworm subunit-1 gi|4895005   48% 
African mosquito   gi|51873091   48% 
Silkworm    gi|158186748  47% 
Honey bee    gi|40806311   44% 
Electric eel alpha   gi|213218   39% 
 
The nAChRα7 does not share high sequence similarity within the alpha subunit 
family, mainly in the amino terminal region, thus expressing greater diversity in 
ligand binding (this is discussed more in Chapter 3).    Interestingly, the coding 
transcript for the nAChRα7 gene expressed by T-cells is not completely identical 
to the neuronal subunit, exhibiting 99.6 % homology and presenting with distinct 
physiological differences92.   
 
Genetic Location  
The gene encoding nAChRα7 (CHRNA7) is located on chromosome 
15q1393.  Physical mapping of the gene indicates the full-length receptor could be 
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greater than 75 Kb in length, contains 10 exons, and is subjected to formation of 
splice variants94.  There is also the existence of a duplicated form of exon 5-10 
that is found 1 million bases from the full-length CHRNA794.  This CHRNA7 
duplicate is found to have an association with a 2-bp deletion found in bipolar 
disorder95.   
 In mice knock-out studies of the nAChRα7 receptor, the animals do exhibit 
loss of bungarotoxin binding and fast synaptic currents.  However, phenotypically 
they seem unaltered except in reproductive ability and neonatal 
development/survival96-98.  Knock-out studies of the receptor have warranted 
further scrutiny due to incomplete loss of immunoreactivity of the receptor; 
however, this could be explained by the presence of the CHRNA7 duplicate or 
antibody selectivity99.  But when anti-sense knockdown studies of the receptor 
were conducted, changes in sensory motor gating and spatial learning were 
noted100.   Knock-in mice created were toxic neonately, but when allele strength 
was diminished the animals were behaviorally modified to show an extreme 
hypersensitivity to nicotine101.    
 
Transcription of CHRNA7 Gene 
 With the mounting data concerning transcription factors in general and the 
use of computer generated models, the identification of regulatory elements that 
control the CHRNA7 is still quite infantile.  The presence of a CNS receptor in 
peripheral tissues makes the picture even less clear.  Also, it has been shown 
the CHRNA7 promoter acts in a cell-type specific fashion102,103.   There is very 
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little known about specific regulatory elements of the CHRNA7 gene.   Table 4 
lists the relatively few factors characterized in animal systems.   
 
Table 4.  Transcription factors known for the AChRα7 receptor. This is the known 
published data regarding transcription factors that act directly on the α7 nicotinic 
receptor promoter.   
 
Species  Transcription factor  Reference 
Cow   Egr-1    Carrasco-Serrano et al.104 
Rat   Egr-1, sp1, sp3  Nagavarapu et al.105   
Mouse muscle USF1, Egr-1   Campos-Caro et al.106 
Mouse lung  TTF-1    Reynold and Hoidal107 
 
The essential promoter region for the human CHRNA7 was established as the 
first 392 base pairs of the promoter from the transcriptional start site.   It was also 
found by computer analysis to have many potential transcription factor binding 
sites within the proximal promoter region as well as possess potential regulatory 
elements up-stream108.  
 
Post-translational Modifications to nAChRα7 Receptor 
 Translational modifications of the nAChRα7 subunit are essential to not 
only cell-surface expression of the receptor but to the functional response 
exhibited by the receptor.  The addition of three asparagine residues to the 
extracellular portion of the nAChRα7 receptor subunit has been shown to be 
essential in the proper folding of the receptor in order to achieve appropriate 
functionality on the cell-surface when expressed in mammalian cells and 
oocytes109.  The importance of glycosylation involving the receptor is represented 
by the mongoose and cobra, with both animals exhibiting an immunity to the 
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toxicity of α-bungarotoxin most likely due to an extra glycosylation site in the 
receptor110,111.  Palmitoylation of the receptor occurs in the endoplasmic 
reticulum before distribution and is essential in the formation of the bungarotoxin 
binding ability exhibited by the nAChRα7 subunit112.  Although it is known to be 
involved in cellular communication, the exact role of palmitoylation in proteins 
has remained elusive, but with the discovery of the enzymes participating in this 
modification more information should reveal the exact function in nAChRα7 
subunits113.    Phosphorylation, like glycosylation, is not involved in cell-surface 
expression, yet Tyr-386 and Tyr-442 in the intracytoplasmic loop are 
phosphorylated and contribute to the proper cellular responses exhibited by the 
receptor114.   In summary, the mature nAChRα7 subunit  is expressed as a 
precursor peptide of 502 amino acids, with a signal sequence of 19 amino acids 
and undergoes several specific modifications that determine the exact location in 
which it is deposited and the proper functioning it exhibits in a species-dependent 
cell-specific manner.  
 
Assembly of nAChRα7 Receptors  
In light of recent evidence, the direct participation of proteins in the final 
processing stages of subunit formation is beginning to unravel some of the 
mystery surrounding the ion channel’s construction.  One protein found to 
participate directly in receptor assembly is RIC-3, resistance to inhibitors of 
cholinesterase [most recently reviewed by Millar 2008115].  RIC-3 has been 
shown to directly bind unprocessed nAChRα7 subunit and is required to 
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participate in receptor subunit folding as a molecular chaperone116.   In the 
absence of RIC-3, little nAChRα7 ligand binding can be detected, where the 
presence of RIC-3 significantly up-regulates production of the functional 
receptor117.  Immunoprecipitation identification using nAChRα7 revealed that 
RIC-3 indeed binds directly to the subunit in the cytoplasmic ER118.  Illustrating 
the importance of the protein in α7 receptor formation are molecular studies 
where RIC-3 mutations resulted in decreased expression of the c. elegans 
nicotinic receptor subunit LEV-1119.  
The function of RIC-3 is essential in the formation of functional α7 homomeric 
ion channels.  However, the accessory proteins that participate in heteromeric 
ion channels have not yet been identified.  Initial studies of nicotinic receptors 
previously only characterized this one nicotinic receptor that used the α7 subunit.  
However, recent data using bovine adrenal chromaffin cells indicates a 
relationship between α3 and α5 nicotinic receptor subunits shown by co-
immunoprecipitation of the receptors with nAChRα7, indicating the possible 
existence of heteromeric α7 nicotinic receptors120.  This recent discovery in 
bovine cells gives strong support to previous findings that identified functional 
heteromeric receptors in rat and chick tissue as well18,121.  The formation of 
homomeric and heteromeric α7 nicotinic receptors would justify the notable 
inconsistencies observed with identification of the nAChRα7 subunit by antibody 
and radioligand binding.  
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Pharmacological Significance of the nAChRα7 Receptor 
 The nAChRα7 receptor has endured considerable scrutiny as a viable 
candidate for pharmacological therapeutic treatment.  This is largely in part due 
to the implications relayed through the smoking populations in such diseases as 
Alzheimer’s and schizophrenia.  In schizophrenia, the use of nicotine appears to 
serve as a “self-medicating” behavior that alleviates the inability to filter 
background stimulus (known as gating deficits) seen in patients122,123.  Generally, 
it has been found that nicotine can improve cognitive functions such as working 
memory in schizophrenic patient populations124.  When nicotine is administered 
with typical antipsychotics used to treat mental illness, there is an improvement in 
cognitive deficits125.  Nicotine up-regulates nAChRα7 expression acutely, as 
verified with experiments in cells and animal models making it a potential target 
for therapeutic benefit91,126,127.   
 The prototype nAChRα7 agonist DMXB-A (3-2,4-dimethoxybenzylidene 
anabaseine) has undergone clinical trials and has been found to normalize the 
gating deficit seen in schizophrenic patients as well as increase other cognitive 
functions128,129.  In animal trials, the nAChRα7 partial agonist, SSR180711, has 
reversed cognitive inefficiencies found in methyllycaconitine (an nAChRα7 
antagonist) administered rats as well as improved anti-depressant behaviors 
possibly by inducing c-Fos production in the prefrontal cortex and the shell of the 
nucleus accumbens130,131.  Several other compounds targeting the nAChRα7 are 
in the developmental phase from the pharmaceutical companies Targacept, 
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AstraZeneca, and Pfizer, which further strengthens the argument of possible 
therapeutic benefits.   
An alternative approach targeting the therapeutic potential of nAChRα7 is 
the use of Positive Allosteric Modulators (PAMs), molecules.  Receptor binding 
events involving PAMs are able to influence the transition between channel 
states that would in turn control the cell surface activity of the nAChRα7 
receptors [recently reviewed by Bertrand and Gopalakrishnan132; Faghih et 
al.133].   Ivermectin and 5-hydroxindole are two well-characterized PAMs that 
have been shown to modulate energy kinetics to produce better effects from 
nAChRα7 agonists134,135.   Most recently, the PAM galantamine has been used in 
clinical trials to supplement nAChRα7 agonist treatment in the therapeutic 
management of schizophrenia with mixed results136,137.  The idea of manipulating 
nAChRα7 activity by the use of therapeutic agents is a very promising area 
regarding the improved prognosis of mental illness.     
 
Recombinant Expression of the nAChRα7 
The limited availability of the human nAChRα7 due to the costly and 
intricate purification procedures from neuronal tissue has not only slowed results 
but led researchers to embark in the development of recombinant expression 
methods for the receptor.    Because relatively little is known about transcriptional 
regulation and translational modifications in combination with the cell-type and 
species-specific expression, the search for an expression system for this 
receptor has proven to be a trial and error effort.  In our laboratory many attempts 
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have been used in an effort to develop or improve nAChRα7 receptor expression 
systems.  Insect cells, sf9, were used as host cells in trying to obtain the entire 
nAChRα7 receptor.  Also, cell free protein synthesis with a variety of expression 
strategies was employed in an attempt to circumvent the problems encountered 
using the receptor.  In the following, the most common recombinant expression 
systems are reviewed for their success in nAChRα7 expression. 
 
Expression of nAChRα7 in Bacteria Expression Systems 
Bacterial cell expression can harbor the production of the nicotinic 
receptor α subunit using techniques specifically designed to overcome the 
negative elements of the system.  Using a trpE fusion vector pATH2, variable 
fragments from amino acids 166 to 315 of the electric eel nicotinic receptor α 
subunit were first expressed in HB101 bacterial cells to characterize ligand 
binding of acetylcholine and alpha-bungarotoxin to the receptor138,139.  A full-
length extracellular construct of amino acids 1-209 of the eel nicotinic receptor α 
subunit receptor was later expressed using a pET 3a vector in the bacterial cells 
BL21 as an inclusion body (100-200mg/Liter) that could be renatured and 
exhibited the ligand binding properties of intact receptors140.   With success 
expressing the amino portion of the torpedo nicotinic receptor, it was found to be 
replicated using the mammalian α7 nicotinic receptor.  A protein over-expressing 
system was developed constructing a fusion protein that consisted of the N-
terminal portion of the rat nAChRα7 (amino acids 1-196), a linker, and maltose 
binding protein that was transformed into XL1 Blue E.coli cells and production 
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occurred at 5 mg/Liter of culture141.  The human extracellular portion of the  
nAChRα7 receptor (amino acids 1-205) could be engineered by fusion to the 
maltose binding protein via the pMAL-c2X vector inserted into E. coli strain BL21, 
which was found to produce a soluble protein at 35mg/Liter142.   
 
Expression of nAChRα7 in Yeast Expression Systems 
Yeast systems provide the necessary cellular organization of eukaryotic 
organisms but exist in single cell entities that are easily maintained and can be 
manipulated to support genetic alterations.  The yeast strain, Saccharomyces 
cerevisiea, was able to support α-subunit expression of the Torpedo californica 
full-length nicotinic receptor at 1% of all membrane proteins present, which 
indicates sufficient translational modifications are made for proper membrane 
insertion143.  Later, it was found that modifications to the hydrophobic Cys-loop in 
the amino terminal of the nAChRα7 receptor led to the production of a soluble 
form of the first 209 amino acids in Pichia pastoris yeast cells, which were 
suitable for structural and physiological studies144,145.   
 
Expression of nAChRα7 in Insect Expression Systems 
Using insect cells to express mammalian proteins offers several 
advantages:  proper folding, less stringent growth conditions, and many proteins 
report post-translational modifications identical to that of mammalian expression 
systems.  The insect cells, Sf9, were used to express the muscular alpha subunit 
from bovine using a viral vector, requiring a rigorous isolation process using a 
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zwitterionic detergent in conjunction with many chromatography steps to produce 
a milligram quantity of the receptor146.  Chick neuronal nicotinic acetylcholine 
receptor α subunit was also successfully expressed using a baculoviral 
expression system in Sf9 cells, but at very low levels.  However, with human 
nAChRα7 it would appear the insect cell system is not conducive for recombinant 
expression of neuronal nAChRα7.  It is reported that upon transfection with the 
CHRNA7 gene, the sf9 cells exhibited variable mRNA expression of a single 
transcript but did not yield functional ligand binding protein, suggesting that the 
insect cell system does not adequately support the post-translation packaging 
required for proper nAChRα7 expression147.   This would appear to be supported 
by our own studies using a baculovirus system in Sf9 cells where human 
nAChRα7 was not detected (data not shown).  It is worth noting that those 
working with the insect nAChRα7 are still asking for development of better 
molecular tools to explore this receptor, even after many years of searching148.   
 
Expression of nAChRα7 in Mammalian Systems 
The human nAChRα7 seems to only be properly expressed in its entirety 
in a mammalian expression system.  Several human neuronal cell lines have 
been shown to express the nAChRα7 endogenously, leading them to be viable 
candidates for an over-expression system for the receptors, but these cells have 
exhibited variable results when trying to use them to genetically engineer the 
receptor.  Rat CHRNA7 was introduced into nine different mammalian cell lines 
(the first three are non-neuronal):  CHO, COS-7, HEK-293, N1E-115, NCB20, 
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Neuro-2A, NG108-15, PC12, and SHSY5Y cells, with only the latter two 
exhibiting increased bungaroxin binding receptors on the cell surface149.  A 
supplemental study also revealed that rat PC12 and human SHSY5Y cells have 
been shown to express functional nAChRα7 receptors with or without mutations, 
while the rat pituitary GH3 cells exhibited variable expression when just the 
mRNA transcripts for the receptor were analyzed147,150.  This illustrates the 
precise cell-specific processing that is required for proper expression of the 
receptor.  However, human neuronal cell lines do not serve well as an over-
expression protein system, which led researchers to look at other cells that could 
effectively express the receptor at more desirable protein levels.  The rat 
fibroblast cells NIH-3T3 did not serve as a viable system exhibiting variable 
expression levels of rat nAChRα7147.  A chimeric protein consisting of the N-
terminal human nAChRα7 fused to the mouse C-terminal of the serotonin 5HT3 
receptor was developed in HEK293 cells to assess pharmacological profiles of 
novel agents to further understanding of the receptor151.  It was also discovered 
that human CHRNA7 can be functionally expressed in HEK293 cells only when 
co-expressed with a human protein known as RIC-3, allowing this system to 
serve as a possible, robust expression environment for nAChRα7118.   The null-
nAChRα7 epithelial cell line, SH-EP1, exhibits a vigorous expression setting that 
can be genetically manipulated to produce the human nAChRα7 receptor as a 
complete, functional native ion channel that can serve as an ideal model for 
molecular studies regarding the receptor152-154.   Several expression systems for 
nAChRα7 using mammalian cells are now in place that can be used as high-
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throughput screening tools in the quest for better understanding regarding the 
complex nature of this receptor.  
 
Expression of nAChRα7 in Cell-free Systems 
Cell-free expression systems are available for researchers to use a 
simple, quick, and sometimes fairly cost-efficient means to protein expression 
when compared to their cell system counterparts.  This expression environment 
has been explored concerning nAChRα7.   The TNT™ quick coupled system 
from Promega used rabbit reticulocytes and expression machinery for insertion of 
fully formed glycosylated chick nAChRα7 into lipid bilayers that exhibited proper 
channel formation155.  Our lab was unable to express full-length human nAChRα7 
using the TNT system but was able to express the first 202 amino acids of the 
extracellular portion as identified by autoradiography and Western blotting (data 
not shown).  To ensure proper post-translational modifications are made to the 
recombinantly expressed receptor, the insect cell-free Easyxpress™ system was 
also used to produce the extracellular portion of nAChRα7.  Protein was created 
but not to a level that would render it economically valuable to use as an over-
expression system by our lab (data not shown).  A cell-free system can 
effectively produce fragmented peptides of the α7 receptor; however, like the 
other expression systems, it appears the nature of the entire nAChRα7 requires 
cell-specific factors that facilitate proper modifications that can result in functional 
receptors. 
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Expression of nAChRα7 in Systems Utilizing RIC-3 
With the discovery of RIC-3 as a chaperone protein directly participating in 
nAChα7 expression, recombinant production using this protein has now begun to 
emerge.  Xenopus expression was the first system to use recombinant nAChRα7 
production upon discovery of RIC-3 to validate the relationship between 
chaperone and receptor118,156.  Several mammalian cell lines have been tested 
for the ability to efficiently produce the nAChRα7 receptor, including HEK293, 
Kidney ts201, and CHO-K1118,157,158.  Most recently, insect RIC-3 homologues 
have been investigated in an attempt to uncover the reason behind the 
inefficiency of insect cells as an expression system for the nAChRα7 receptor157.   
The presence of RIC-3 has opened avenues to develop potential nAChRα7 over-
expressing systems in an effort to provide the tools necessary in identifying the 
precise role the receptor occupies in the pathophysiology of various mental 
disorders. 
Advances in the research and development using the nAChRα7 subunit 
have initiated the development of this frontier in the study of mental illness.  The 
important role the receptor is assuming in the patho-physiology of various 
diseases, coupled with the emerging pharmacological significance exhibited, is 
making the complete understanding of the receptor vitally important.  The 
information garnered by the various cell-specific or cell-free systems expressing 
the receptor is aiding in the development of a more complete picture of what 
could be groundbreaking therapeutic treatment in mental illness.     
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CHAPTER 3 
INCREASED SERA ANTIBODIES FOR THE α7 SUBUNIT OF THE NICOTINIC 
RECEPTOR IN SCHIZOPHRENIA 
 
Background 
Insight regarding the complex etiology of schizophrenia may lie in one of 
its most well-known symptoms, auditory hallucinations (AH).  One abnormality 
that has been described in schizophrenia, that may contribute to AH, is inefficient 
auditory gating, which is the ability to filter background stimuli and focus on a 
single auditory stimulus.  The α7 subunit of the acetylcholine nicotinic receptor 
(α7nAChR), which has low affinity binding to nicotine, has been associated with 
normal auditory gating76.  Involvement of the nicotinic receptor family in 
schizophrenia is suggested by increased tobacco use in the diagnosed patient 
population, which is between 85% and 90%; this rate is more than triple the 
normal use and could indicate a self-medication with nicotine159.  Further 
investigations revealed neuronal nAChRα7 had diminished protein expression in 
schizophrenic patients as shown with postmortem ligand binding studies37,160.  
Messenger RNA studies have failed to conclusively support this, identifying post-
translational mechanisms or other factors as the culprit in the abnormal levels 
seen in patients36,37.   Genetic linkage studies identify the receptor as a possible  
candidate gene in schizophrenia161.  The emerging molecular and genetic data 
regarding the nAChRα7 suggests a direct involvement of the receptor in the 
neuropathology of schizophrenia.       
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The nAChRα7 is a ligand-gated ion channel directly involved in the cell 
signaling events that participate in the control of the anti-inflammatory pathway12.  
Early research noted morphological changes in lymphocytes, altered B and T cell 
expression, and increased cytokine circulation in schizophrenic patients162.  A 
clinical study with chronic schizophrenics who were administered a cytokine 
inhibitor along with their antipsychotic regiment improved significantly better than 
those who were not163.   Also in schizophrenia, there is evidence found through 
patient family history evaluations that family members tend to develop other 
autoimmune disorders 164.  There have also been reports of the existence for 
sera antibodies to a muscarinic subunit of the nicotinic receptor in patients with 
schizophrenia165,166.    The evidence suggests an autoimmune mechanism may 
contribute to the schizophrenia, leading to our hypothesis that schizophrenic 
patients possess autoantibodies for the nAChRa7.  The goal of this study is to 
analyze schizophrenic patient blood serum for antibodies exclusive to the 
nAChRα7 receptor.   
 
Materials and Methods 
Patients 
This study was approved by the Institutional Review Board at East 
Tennessee State University.  Patients were required to submit written informed 
consent for any information and blood extraction.  A clinical diagnosis was 
determined upon evaluation based on patient history, therapeutic analysis, and 
completion of the Structural Clinical Interview from the DSM-IV axis of diagnosing 
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psychiatric illness (SCID).  A total of 21 patients were included in the study and 
were classified as having schizophrenia.      
 
ELISA Using Recombinantly Expressed α7 Protein 
The Enzyme-linked immunosorbent assay (ELISA) was used according to 
the following method.  Polyvinyl 96-well microtiter plates were coated with 50 ng 
of recombinant α7 nicotinic receptor (Abnova, Taipei City, Taiwan) produced in 
wheat germ extract diluted the appropriate concentration in Ringer’s buffer (25 
mM Tris pH 7.2, 150 mM NaCl, 5.8 mM KCl, 1.8 mM CaCl2, 1.3 mM MgCl2, .1 
mg/ml sodium azide) and incubated overnight at 4oC.  The plates were blocked 
with tris-buffered saline (TBS) containing 3% bovine serum albumin (Sigma, St. 
Louis, MO) at room temperature for 3 hours.  After one wash with TBS-T (.05%), 
the antigen was incubated with N-terminal α7 antibody at 1:75 dilution (Abcam, 
Cambridge, MA), overnight at 4oC.  Following one wash with TBS-T (.05%), 200 
µl/well of horseradish peroxidase conjugated goat anti-rabbit IgG (1:1000 
dilution) (Southern Biotech, Birmingham, AL) was added to plates and incubated 
for 4 hours at room temperature.  After five washes with TBS-T (.05%), the 
complexes formed in each well were incubated with 150 µl of 1-step ABTS 
(Pierce, Rockford, IL) for 20 minutes, after which 100 µl of 1% SDS was added to 
each well.  The absorbance values were read at 405 nm using a Biorad 450 
microplate reader  (Hercules, CA).   Protein binding was assessed using the N-
term antibody from Abcam as a positive plate control.  The serum anti-α7 
antibody levels were determined using the same experimental perameters as the 
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control antibody.  After antigen binding and plate blocking was complete, serum 
from controls and schizophrenic patients diluted at 1:500 in TBS-3% BSA were 
incubated overnight at 4oC.  Optimal sera binding was initially determined by 
using a dilution curve of patient sera initially ranging from 1:2, 1:10, 1:50, 1:100, 
1:500, 1:1000, and 1:10,000 in TBS-3% BSA.  Each patient and control serum 
was subjected to two dilution samples for verification.  After wash with TBS-T 
(.05%), 150 µl of horseradish peroxidase conjugated goat antihuman IgG (1:1000 
dilution) (Southern Biotech, Birmingham, AL) in TBS-3% BSA was added to wells 
and incubated for 4 hours at room temperature and completed as with the 
positive N-terminal antibody above.   
 
Determining Antibody Activities 
In order to express a similar distribution, the antibody index was calculated 
in the following manner.  The nAChRα7 antibody index was determined as 
percent control of the anti-nAChRα7 polyclonal antibody positive control served 
as a plate standardization and expressed in the following manner: 
 Relative optical density of sample   x 100 
 Relative optical density of positive control  
 
Standard deviation from the mean value was determined for healthy control 
population.  Assay was conducted in triplicate in two separate experiments and 
indices analyzed in their relationship to more or less than two standard deviations 
from the mean.  The relationship between patient/control age and antibody 
indices also used these antibody scores.    Four different statistical analysis were 
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employed to determine statistical significance to control mean, t-test, Fisher’s 
exact test for probability, CHI determination, and a Dunnett probability analysis. 
 
Results 
Serum anti-nAChRα7 antibody indices were higher in some of the patients 
diagnosed with schizophrenia than in the control sample population.  There were 
five patients with a value above +/- 2SD above healthy controls (Figure 10).  
Overall, 23% of the patient population exhibited anti-nAChRα7 antibodies based 
on CHI square analysis.  However, it should be noted when other statistical 
analysis were conducted, the findings were close to the accepted level of 
significance in each one of them:  t-test p=.08, Fisher’s exact test p=.06, and 
Dunnett analysis p=.06. 
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Figure 10.  Antibodies to the nAChRα7 receptor found in Schizophrenia vs. 
healthy controls. A Chi square analysis was formulated to compare the activity 
between the control and patient population.  The line exhibits +/- 2 S.D. levels 
from the control mean.  Indices above this are considered positive for nAChRα7 
antibodies.  Significance was determined at p<.05, where the Chi square value 
was .03.   
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Figure 11.  The linear comparison of antibody titer to age in the patient 
Population Compared to Controls.  Both regression coefficient and ANOVA 
analysis was used to test the relationship between age and titer.  Anti-nAChRα7 
antibodies correlate with age according to ANOVA analysis with a p-value <.009.   
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There were significant differences in the two populations with regard to 
age and anti-α7 receptor antibodies.  The patient group was found to significantly 
exhibit a strong correlation between age and antibody index, where as the control 
group exhibited no significant correlation between nAChRα7 antibody in age-
matched controls (Figure 11).  Shown in Table 5 are the clinical characteristics in 
the patients who had higher activities of nAChRα7 antibodies, as shown with 
similar age-matched controls.   
Table 5.   Clinical characteristics.  These are the clinical characteristics of four of 
the five schizophrenic patients with elevated α7 receptor (nAChRα7) levels, as 
well as the clinical characteristics of close age-matched controls.    
 
 
Patient  
Number/Diagnosis Age/Sex Other known factors Antibody index 
1/SCH  60/M  Depression   682 
2/SCH  61/F  -    637 
3/SCH  46/M  Anxiety   488 
4/SCH  50/F  -    486 
 
5/CON  61/F  -    321 
6/CON  71/M  -    292 
7/CON  47/M  Depression   211 
8/CON  43/F  -    373 
 
 
 
Discussion 
In this study, the sera of patients with schizophrenia were examined for 
antibodies targeting the nAChRα7 subunit.  It was found there are elevated levels 
in the patient population when compared to a non-Schizophrenic control 
population.  The information indicates a pathogenic level of nAChRα7 antibody 
may actively contribute to the etiological basis of the disease in at least a subset 
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of patients.  Even more interesting is the increased levels of antibody with regard 
to age, which mirrors the neurodegenerative nature of the disease.    
The nAChRα7 receptors are extremely important in the modulation of 
glutamate and GABA neurotransmitter release and antibodies specific to the 
receptor may interfere with those events.  Also, sera antibodies for the receptor 
may result in targeting the cell for degradation by the immune system, which 
would certainly justify the down-regulation of the receptor that has been found by 
ligand binding assays in the brains of schizophrenics 35,83.      
The findings in this study also contribute to understanding of nAChRα7 
role in the immune system.  This acetylcholine receptor, once thought to be 
confined only to the central nervous system, has now been identified in epithelial 
cells and in blood leukocytes69,167.  The presence of the receptor on leukocytes 
has provoked investigations into the relationship with the immune system.  It was 
found that nAChRα7 receptor activation participates directly in restoring the 
delicate balance between the pro-inflammatory and the anti-inflammatory 
pathways.  Signaling by the receptor prevents nuclear translocation of NFkB, a 
cytokine regulatory transcription element, that effectively silences the pro-
inflammatory pathway.  Simultaneously, the nAChRα7 activates the JAK/STAT 
pathway, initiating the anti-inflammatory response12.  If nAChRα7 receptor 
activation were reduced by antibody binding events, a loss in control of these 
inflammatory molecules would result as exhibited in the immune system of some 
schizophrenic patients12.        
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If receptor function can be altered by the presence of auto-antibodies in a 
subgroup of patients with schizophrenia, then pharmacological manipulation 
targeting the receptor could be productive in disease management.  A clinical 
trial with DMX-B, a nAChRα7 agonist, found cognitive improvements in 
schizophrenic patients128.  More recently, the combined therapy of CDP-choline 
(nAChRα7 agonist) and galantamine (nAChRα7 positive allosteric modulator) 
conducted in a 12-week trial of 6 schizophrenic patients was found to lessen the 
severity of the disease136.  Currently, pharmaceutical companies Pfizer, Astra-
Zeneca, Pharmacia, Targacept, and Sanofi-Adventis all have nicotinic agonists in 
development131,168.   Along with development of synthetic molecules is the use of 
immunotherapy with peptide fragments of the nAChRα7, resulting in the induction 
of spatial memory in an Alzheimer’s animal model indicating a novel treatment for 
cognitive deficits in schizophrenia169.  By establishing a relationship between the 
α7nAChR, auto-antibodies, and schizophrenia, a causative factor could be 
identified and better therapeutic interventions designed for a specific target in a 
manageable subset of patients.     
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CHAPTER 4 
FUNCTIONAL CHARACTERIZATION OF THE CRE HALF-ELEMENT FOUND 
IN THE PROMOTER REGION OF THE NICOTINIC RECEPTOR α7 SUBUNIT  
 
Background 
 
Regulation of human gene expression has been the subject of intense 
scrutiny when it comes to identifying the mechanisms behind neurotrophic 
responses to external stimuli.  There are hundreds of different transcription 
regulatory proteins known, with the average gene requiring two dozen factors to 
form one transcriptional complex.  The number of proteins required for one 
transcriptional complex multiplied by the different complexes necessary to 
participate in the precise expression pattern exhibited by a specific gene results 
in an exponential number of scenarios.  Knowledge regarding gene expression 
will continue to grow as the protein interactions with the human genome are 
identified.  One of the most widely investigated regulatory elements in neuronal 
processes has been the cAMP-response element binding protein (CREB) family 
of transcription factors.   CREB has been shown to be involved in neuronal 
development, circadian rhythm regulation, learning and memory, neurotrophic 
responses in the cell, and precursor proliferation170.  The transcription factor 
CREB binds specific DNA sequences known as cyclic-AMP response elements 
(CRE).  In the human genome, there have been 10,447 full CREs and 740,390 
half CREs identified in an approximate 3300 bp range relative to potential 
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transcription start sites171.  Zhang and associates used three different algorithms 
to reduce/refine the above projection to 4,084 putative CREB target genes172.   
Because of the growing relationship between CREB-regulated gene 
expression and neuronal processes, research has greatly intensified to establish 
this pathway as a therapeutic target.  Antidepressant treatment results in an up-
regulation of CREB, supporting the hypothesis that CREB-driven regulation of 
target genes contribute to neuronal plasticity and neurogenesis that result in 
behavioral effects173.   Treatment with lithium for mood disorders results in 
neuronal survival via an up-regulation of CREB174.   Prognosis following brain 
insult markedly improves following treatment with agents such as somvastatin 
due in part to neurogenesis stimulated through increased CREB 
phosphorylation175.   Tardito and associates specifically note that CREB-
dependent gene transcription not only relies on a particular pharmacological 
agent but also the specific neuronal area targeted176.  Nicotine illicits a 
neuroprotective effect via CREB resulting in improvement in long-term 
potentiation (LTP) and spatial memory in the CA1 area of the hippocampus177.  
The regulatory element CREB has a complex role in regulating many of the 
genes involved in proper neuronal function.    
Post-mortem studies have shown a decrease in the α7 nicotinic receptor 
in brains of diagnosed schizophrenic patients178.  Pharmacological studies have 
demonstrated that treatment of animal subjects with agonists specific to the α7 
subunit of the nicotinic receptor (nAChRα7) produced enhanced LTP resulting in 
a decline in cognitive defects, in particular with those associated with 
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schizophrenia179,180.  The proximal promoter region of the α7 subunit has a 
potential CRE site identified by computer analysis.  This could be a functional 
regulatory element supported by the finding that null-CREB mice exhibit a 
decreased level of receptor181.  Based on this information, we hypothesize 
nAChRα7 expression could fall under CREB control, either in the initial 
transcription complex formation or as a signaling mechanism during the 
translation process.  This study aims to test this hypothesis by exploring what 
role, if any, the half-CRE element found in the promoter of the nAChRα7 
occupies in the transcriptional regulation of nAChRα7 receptors.     
 
Materials and Methods 
 
Cell Culture 
Human neuroblastoma cell line SHSY5Y cells were grown in Ham’s F12 modified 
Eagle’s media supplemented with 15% fetal bovine serum and 1% non-essential 
amino acids all from Sigma Chemical Company (St. Louis, MO) in an 
atmosphere containing 5% CO2 in air at 37oC.  Human recombinant CREB was 
purchased from Prospec (Rhehovet, Isreal). 
 
EMSA (Electromobility shift assay) 
A 21-bp complimentary oligonucleotide, 5’ GCGGGGCTCGTCACG TGGAGA 3’, 
and a 45-bp complimentary oligonucleotide 5’ ACGGGG 
GCGGGGGCGGGGCTCGTCACGTGGAGAGGCGCGCGGGGGC3’, as well as 
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mutated α7 promoter regions (Figure 13A), containing the putative CRE motif of 
the α7 promoter were subjected to EMSA using a Gel shift assay kit according to 
the  manufacturer’s instructions (Promega, Madison, WI).  Also used was positive 
control CRE motif oligonucleotide (Promega, Madison, WI).  Oligonucleotides 
were 5’ end-labeled with a radioactive phosphorus, and Protein-DNA complexes 
were separated on a 4% non-denaturing PAGE gel.  Competition assay used 
50X unlabeled probe.  Antibody assays used 1 µg of polyclonal anti-CREB 
antibody (Rockland, Gilbertsville, PA) and anti-Sterol Response Element Binding 
Protein (Santa Cruz, CA). 
 
Construction of Reporter Plasmids 
The promoter sequence from the α7 subunit of the nicotinic receptor containing 
the suspected transcription factor motif was created using PCR amplification of 
genomic DNA isolated from human brain (Biochain, Hayward, CA) using the 
following primers:  sense 5’AGA ACG CAA GGG AGA GGT AGA 3’ and anti-
sense 5’ GTT GAG TCC CGG AGC TGC AGC GA 3’.  The 392-bp fragment was 
then cloned into TOPO pCR2.1 vector (Invitrogen, Carlsbad, CA) via Kpn I and 
Xho I restriction sites resulting in the pCR2.1/ α7 vector.  The promoter was 
subsequently removed from this vector and subcloned into the pGL3-basic 
luciferase reporter vector (Promega, Madison, WI) by Kpn I and Xho I sites 
resulting in pGL3-α7.  Nucleotides within the promoter -151 to -172 were then 
subjected to site mutagenesis using the Quikchange kit (Stratagene, Santa 
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Clara, CA) following manufacturer’s instructions, resulting in the pGL3-mα7 
vector.   All DNA was verified by sequencing.      
 
Transfections and Reporter Gene Assays 
SHSY5Y were plated in a 96-well plate at a density of 10,000-15,000 cells per 
well.  The following day, cells were transfected with pGL3-b, pGL3-positive 
control, pGL3-α7, and pGL3-M α7 vectors in triplicate using the FuGene HD kit 
for lipotransfection following manufacturer’s instructions (Roche Diagnostics, 
Indianapolis, IN).  Firefly luciferase was normalized to the activity of renilla 
luciferase by co-transfecting pRL-SV40vector.  Cells were harvested at 24, 48, 
72, and 96 hours for reporter gene assays.  Cells were lysed and luciferase 
assayed using the Dual Luciferase Reporter Assay System (Promega, Madison, 
WI).  Cells in some experiments were treated with DMSO vehicle or 10 µM 
forskolin (4, 12, and 24 hours).  In other experiments, cells were transfected with 
1 ug total of pGL3-α7 control, pGL3-α7 control + shuttle DNA, pGL3-α7 + pCMV-
CREB, pGL3- α7 + pCMV-KCREB.  Dominant negative CREB vectors were 
purchased from Clontech (Mountain View, CA).  
 
Chromatin Immunoprecipitation 
SHSY5Y cells were incubated with 25 µM of forskolin (Sigma, St. Louis, MO) for 
20 minutes.  Cells were cross-linked for 10 minutes using 1% formaldehyde.   
Cross-linking was then stopped using glycine.  Cells were manually harvested 
and pelleted.  Cells were lysed using detergent and dounce homogenizing.  
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Nuclei were then collected and resuspended in shearing buffer then sonicated 10 
times for 10 seconds on ice.  Sheared chromatin samples were centrifuged at 
14000 rpm at 4oC. Chromatin samples were then pre-cleared for 2 hours at 4oC 
using 80 µl of 50% Protein-G sepharose (Pierce, Rockford, IL), 250 µl of sheared 
chromatin, 250 µl of immunoprecipitation buffer, 5 µl of protease inhibitor cocktail 
(Sigma), 1 µg/ul BSA (Fisher Sci), and 4 µg/ml poly dI-dc-poly-dI-dc (Sigma, St. 
Louis, MO).  Pre-cleared samples were then incubated with polyclonal CREB-
antibody, or anti-mouse antibody, overnight.  Antibody complexes were then 
recovered by adding 100 µl of Protein G-sepharose beads and incubated 4 hours 
at 4oC with rotation. Bead complexes were then washed 4 times with immuno-
precipitation wash buffer.  Chromatin was then eluted using an SDS solution.  
The eluates were digested with 10 mg/ml RNAase and 0.3 M NaCl overnight to 
reverse crosslinks and digest RNA.  Samples were then digested with 0.1 mg/ml 
Proteinase K and cleaned using the Wizard SV kit according to manufacturer’s 
instructions.  DNA was then amplified by PCR using α7 promoter primers, 
5’AGAACGCAA GGGAGAGGTAGA 3’ sense, 
5’GTTGAGTCCCGGAGCTGCAGCGA 3’antisense 
 gel purified, and verification made by DNA sequencing.  Subsequent 
experiments were conducted utilizing the ActiveMotif ChIP-it Express with 
Enzymatic Shearing following manufacturer’s instructions (Carlsbad, CA).  PCR 
products were subjected to verification by DNA sequencing.   
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Western Blot 
Western blot was performed with anti-CREB antibody (Rockland, Gilbertsville, 
PA).  α7  oligonucleotides were used and incubated with SHSY5Y nuclear protein 
as in EMSA.  Nuclear lysate was isolated by incubating 5 x106 cells with 2 ml of 
the following: 10 mM Hepes, 10 mM KCl, .1 mM EDTA, .0004% Igepal, 
antiproteolytics (DTT, Pepstatin, Leupeptin, PMSF) directly in 150 mm plate and 
subjected to manual harvest.  After which the cells were disrupted by sonication 
and nuclei were pelleted by centrifugation for 3 minutes at 14,000 x g. Nuclei 
were then suspended in 20 mM Hepes, .4M NaCl, 1mM EDTA, antiproteolytics 
(DTT, Pepstatin A, Leupeptin, PMSF) vigorously mixed for 2 hours at 4oC, and 
centrifuged at 14,000 x g for 5 minutes to recover nuclear proteins.  Protein/DNA 
oligo complexes were separated on a 4% polyacrylamide gel.  Proteins were 
transferred to nitrocellulose and nonspecific sites blocked using 5% milk.  The 
blot was incubated with 1/1000 dilution of p43 anti-CREB (Rockland, Gilbertsville, 
PA) and then with 1/20,000 anti-rabbit.  The blot was washed three times with 
TBS-T .05% for 10 minutes and developed with Pico Supersignal (Pierce, 
Rockland, IL).  
 
RNA Extraction and end point RT-PCR 
RNA was extracted from SHSY5Y cells using the RNAqueous micro (Ambion, 
Austin, TX) according to manufacturer’s instructions.  In some experiments the 
SHSY5Y cells were treated with DMSO mock, 10 µM forskolin for 4, 12, and 24 
hours or transfected with pCMV-CREB, pCMV-KCREB and empty vector 
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harvested after 24 hours.  RNA was reverse transcribed into single strand cDNA, 
and RT-PCR were carried out using the following primers specific for nAChRα7, 
sense 5’ CGCCACATTCCACACTAAC 3’,  and antisense 5’ ACC TTT CAC TCC 
TCT TGC C 3’ .  Each reaction contained 20 pmol 5’, 3’ primer, 5 units Taq, 
10µM DNTP’s, 10X reaction buffer, varying degrees of template DNA conducted 
at 95oC for 5 minutes, followed by 30 cycles of 94oC, 61oC, and 72oC.  Primers 
for β-actin were used as a control under same conditions with a cycle number of 
24, sense 5’ TCA CCC ACA CTG TGC CCA TCT ACG A 3’ and antisense 5’ 
CAG CGG AAC CGC TCA TTG CCA ATG G 3’.   
 
Results 
Ectopic CREB Protein does Stimulate Expression of nAChRα7 
 Messenger RNA was used to analyze the expression of the nAChRα7 
receptor in SHSY5Y cells that were subjected to a raise in the level of ectopic 
CREB.  The mRNA level of α7 was significantly higher in SHSY5Y cells that were 
transfected with pCMV-CREB vector that expresses wild-type CREB than were 
control levels.  Cells transfected with the pCMV-KCREB were found to have 
lower levels of the receptor (Figure 12A, lane 4).  Figure 12B shows forskolin 
treatment, which induces phosphorylated CREB, did not significantly affect the 
production of nAChRα7 transcripts.  This study is focused on the validation of the 
half-CRE element conserved in the human nAChRα7 promoter.   
 73 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12.  Potential regulation of nAChRα7 expression by CREB.  In panel A 
total RNA was extracted from untreated SHSY5Y cells (control), cells transfected 
with pGL3-b vector (mock), pCMV-CREB (wild type CREB), and pCMV-KCREB 
(CREB mutant) and expression of  mRNA was analyzed by RT-PCR using 
primers found in materials and methods.  Β-actin was used as control for cDNA 
input, PCR was performed, and virtual gel analyzed using Agilent 2100 software.  
Panel B shows various treatments involving SHSY5Y cells, where total RNA was 
extracted from untreated cells, cells treated with 10 µM forskolin (FSK) for 12 
hours.  β-actin was used as control for cDNA input, PCR was performed, and 
virtual gel analyzed using Agilent 2100 software.  Asterisk * denotes significance 
p<.05, assay conducted in triplicate.   
 
Binding of CREB to α7 Subunit of the Nicotinic Promoter 
The suspected CRE-element is not a concensus CRE binding sequence 
with the perfect palindrome TGACGTCA; instead, it takes on a half-element form 
which has been proven to be sufficient enough to bind CREB and initiate 
transcription (Table 6).   
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Table 6.  Functional half-CRE elements.  Genes found to exhibit CREB protein 
binding to the non-concensus DNA CRE half-element (CGTCA)         
 
Gene  Description     Reference        
Phox2A  Proneural transcription element   182 
Oatp2  Anion transport protein    183 
UCP1  Mitochondrial uncoupling protein  184 
ppN/OFQ Prepronociception gene    185 
EF-2  Peptide chain elongation   186 
 
 
Various nAChRα7 oligonucleotides were constructed, with mutations introduced 
to the crucial CG that is essential for CREB binding (Figure 13A).  Using nuclear 
proteins extracted from SHSY5Y cells, the nAChRα7 oligonucleotides formed 
four different complexes in the EMSA.  Introduction of mutations in the crucial CG 
regions were found to completely abolish one of the complexes (Figure 13B).  
Findings were replicated using recombinant CREB protein, where anti-CREB 
antibody validated a unique CREB interaction by creating a super shift in the 
banding pattern (Figure 13C).  To indicate specificity, α7 subunit promoter 
(denoted in figure by α7) complexes were subjected to competition assays using 
50-fold excess of unlabeled oligonucleotide with varying CRE sequences, with 
only the concensus CRE-element introduced into the α7 subunit promoter (cα7) 
found effective enough to compete for binding to the radioactive α7 CRE-element 
(Figure 13C).  The flanking sequences are not solely responsible for the bound 
complexes because the crucial CG-mutated α7 subunit promoter (mα7) with 
intact α7 subunit CRE half element flanking regions were found to ineffectively 
compete for binding to the radiolabeled α7 promoter (Figure 13D).  This indicates 
that the flanking regions could contribute to protein stability, but the crucial CG 
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nucleotides present in the CRE half-element are an important factor in the 
stabilization process of complex formation.    
 
 
            
      
 
 
 
 
 
 
 
 
 
 
 
        
 
 
 
 
 
 
 
 
 
 
Oligonucleotide used in the following 
cc                           5’  agagattcgcTGACGTCAgagagctag 3’ 
α7    -184  5’acgggggcgggggcggggctCGTCAcgtggagaggcgcgcgggggc3’   -138 
mα7 -184  5’acgggggcgggggcggggctTATCAcgtggagaggcgcgcgggggc3’   -138 
cα7  -184  5’acgggggcgggggcgggTGACGTCAcgtggagaggcgcgcgggggc3’   -138 
sα7  -172                5’           gcggggctCGTCAcgtggaga  3’                        -151 
 
A 
B 
rCREBhu SHSY5Y
cc        α7       mα7     cα7       cc        α7        mα7     cα7  
Unbound Oligo
CREB complex
CREB complex
 
-392 bp +1
CRE half-element
-164
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Figure 13.  EMSA assays illustrating CREB binding to the CHRNA7 promoter. Lanes 1-4 in panel 
A are different CRE-like element oligonucleotides radiolabeled with P-32 ATP incubated with 
rCREBhu protein separated on a 4% nondenaturing polyacrylamide gel.  Lanes 5-8 are the CRE 
oligonucleotides incubated with SHSY5Y nuclear lysates.  Lanes 1 and 5 are the consensus CRE 
element purchased from promega.  Lanes 2 and 6 are the CHRNA7 promoter with the CRE half-
element.  Lanes 3 and 7 are the CHRNA7 promoter with a mutation in the crucial CG in the CRE 
element.  Lanes 4 and 8 are the CHRNA7 promoter with a concensus CRE-element insert.  (B)  
EMSA supershift assay using anti-CREB antibodies.  Lane 1 is CHRNA7 radio-labeled 
oligonucleotide incubated with rCREBhu protein in the presence of anti-CREB antibody.  Lane 2 
is radiolabeled concensus CRE oligonucleotide (Promega) incubated with rCREBhu protein with 
anti-CREB antibody.  Lane 3 is radiolabled oligonucleotide incubated with rCREBhu protein, no 
antibody.  Lane 4 is free 32P labled CHRNA7 probe.   Panel C is competition assays using radio-
labeled CHRNA7 oligonucleotide complexes formed with rCREBhu protein in which 100-fold 
excess of indicated unlabeled probe was introduced to the reaction.   
 
Specific CREB binding to the CRE half-site of the CHRNA7 promoter in-
vitro was explored through the use of SHSY5Y neuroblastoma cells that 
endogenously produce the α7 receptor.  Nuclear lysate from SHSY5Y cells was 
incubated with the unlabeled oligonucleotides used in the previous gel shift 
assays shown above.  Complexes formed between nuclear protein and α7 
oligonucleotides were separated on a polyacrylamide gel and then subjected to 
Western blotting using anti-CREB antibodies.  The concensus CRE element 
probe and the α7 probes were positively identified by anti-CREB antibodies in 
complexes formed with CREB, while the nonspecific (sp1) and mutated α7 probe 
Control CRE              - +                     - -
CHRNA7 CRE           +                     - +                   -
Anti-CREB                +                     +                     - -
1                    2                  3                 4 
 
Competitor        - sα7        cc          mα7      cα7                
1             2            3            4            5 
 
C D 
 77 
failed to be associated with CREB (Figure 14A).  To further illustrate CREB 
specificity, oligonucleotides of the α7 CRE half-element, mutated α7 CRE-
element, and a consensus CRE-element were labeled with biotin and used as 
bait in SHSY5Y cell lysate to probe for CREB binding as indicated in Figure 14B.  
Only the mutated α7 CRE element failed to be extracted using the biotin-avidin 
interaction.  These findings were validated invivo where immunoprecipitation with 
anti-CREB antibody was used to extract chromatin fragments that had been 
chemically cross-linked to nuclear protein.  Chromatin/DNA complexes were 
isolated directly using anti-CREB antibodies, upon which PCR amplification, 
using primers specific for the proximal promoter region of the α7, was able to 
positive identify CREB binding to the half-CRE element (Figure 14C).   
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Figure 14.  The invitro and invivo identification of CREB protein bound to the 
CHRNA7 CRE half-element in the promoter region.  Panel A) Protein/DNA 
complexes were separated on 4% acrylamide gel, then probed with CREB p43 
antibody (Rockland, MD).  Lane 1 is consensus CRE-element (Promega), Lane 
2, α7, is CHRNA7 promoter CRE-like element, Lane 3, mα7, is CHRNA7 
promoter CRE half-element with crucial CG mutation, Lane 4 is Sp1 
oligonucleotide (Promega, Madison WI), Lane 5 is protein only without DNA.  
Panel B is the identification of CREB binding using oligonucleotides labeled with 
biotin, incubated with SHSY5Y nuclear lysate and captured using avidin coated 
magnetic beads (Invitrogen, Carlsbad, CA).  Complexes were resolved on a 10% 
SDS polyacrylamide gel and probed using anti-CREB antibodies (Santa Cruz, 
CA).  Lane 1 is CHRNA7 promoter, lane 2 is mutated CHRNA7, and lane 3 is 
CHRNA7 promoter with consensus CRE insert.  Panel C is chromatin from 
SHSY5Y cells immunoprecipitated using anti-CREB antibodies.  SHSY5Y cell 
protein was cross-linked to DNA using a 1% formaldehyde solution, DNA was 
extracted and subjected to PCR using primers for the CHRNA7 essential 
promoter.  PCR amplification in lane 1 uses DNA isolated from crosslinked 
chromatin using CREB antibodies trial 1, lane 2 uses SHSY5Y cDNA, lane 3 is 
negative control mock immunoprecipitation, lane 4 is DNA isolated from cross-
linked chromatin using CREB antibodies trial 2, lane 5 is DNA isolated from 
cross-linked chromatin using CREB antibodies trial 3, and lane 6 uses DNA from 
pGL3 with CHRNA7 promoter insert as positive control.   
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Functionality of CRE Half-element in the CHRNA7 Promoter  
To explore the functionality of the CRE half-element present in the 
CHRNA7 promoter, a luciferase reporter gene assay was used.   A 392 base pair 
fragment, denoted as the essential promoter, of the CHRNA7 promoter (-1 to -
392) was inserted into the pGL3-b-Luc vector to produce pGL3-α7.  This vector 
was transfected into SHSY5Y neuronal cells and luciferase activity was 
measured.  This part of the promoter had previously been examined in this 
manner and found to exhibit transcriptional activity.  To begin to explore a more 
specific relationship with CREB, mutations were introduced into the crucial CG 
base pairs of the suspected CRE half-element of the pGL3-α7 luciferase 
construct and pGL3-mα7 luciferse activity was compared in the two vectors.  
When transfected in SHSY5Y cells, the CG mutated promoter exhibited 
significantly lower expression levels than the wild-type α7 promoter (Figure 15).    
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Figure 15.  Functionality of the CRE half-element is evaluated by luciferase 
reporter gene assays. This is the functional analysis of point mutations in the 
CHRNA7 promoter by a luciferase reporter gene assay.  Neuronal cells, 
SHSY5Y, were transfected with different plasmid constructs to assess the 
function of the α7 promoter.  Striped bars represent transfections with the 
luciferase vector pGL3 under the control of the α7 promoter.  Dark bars represent 
transfections with the luciferase vector pGL3 under the control of a mutated α7 
mutated promoter in which a crucial CG in  the CRE-like region was mutated to a 
AT.   Promoter activity was assessed by measuring firefly luciferase activity and 
expressing in percent control of renilla luciferase.   The FugeneHD transfection 
reagent was used per 2 µg of pGL3-DNA per 15,000 cells, co-transfected with 
0.2 µg of pRL-SV40.  All units were expressed as percent control to the protein 
produced by the pRL-SV40 vector.  
 
 To look at the detailed relationship CREB plays in expression of  receptor, 
the CHRNA7 constructs used in the luciferase reporter gene assays were co-
transfected with either pCMV-CREB (expresses wild-type human CREB) or 
pCMV-KCREB (forms dominant-negative heterodimer with CREB).  The data 
revealed that expression of the wild-type α7 promoter is upregulated substantially 
when in the presence of overexpressed wild-type CREB.   In the presence of the 
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dominant repressor KCREB, which acts to form a dimmer with CREB that 
effectively blocks the ability to bind CRE elements, transcriptional activity was 
reduced in comparison to wild type CREB.  These results show the α7 promoter 
is affected by CREB binding.  However, the α7 promoter, where the crucial CG 
for CREB binding was mutated, behaved in the same manner (Figure 16).  This 
indicates the α7 CRE half-element investigated here is not solely responsible for 
the increase in CREB controlled transcription of the α7 subunit.     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16.  Dominant-Negative CREB mutants affect α7 transcription.  SHSY5Y 
neuronal cells were transfected with pGL3α7 (under wild type a7 promoter) or 
pGL3-ma7 (containing a crucial CG mutation to CRE element) vector.    The 
striped bar in each time frame exhibits activity where promoter was co-
transfected with wild-type CREB.  The dark bar is luciferase activity when pGL3-
α7 co-transfected with pCMV-KCREB.  Promoter activity was assayed by 
measuring firefly luciferase activity.    All bars represent the mean +/- SD 
assayed in triplicate.  
 
 
 Further investigation involved forskolin treatment SHSY5Y neuronal cells 
transfected with either pGL3a7 or pGL3-ma7.  The data indicate that treatment 
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did not initiate in transcription of the wild-type alpha7 promoter; rather, it resulted 
in a down-regulation of the promoter after a 24 hour treatment (Figure 17).  
However, the mutant vector did not respond in the same manner to forskolin 
treatment.  This reveals the crucial mutation to the CG in the CRE-like element 
does alter production of the promoter in response to PKA activated CREB.  The 
firefly luciferase results clearly show that CREB is directly involved in the 
production of α7 subunit, but it may be an interaction of CREB heterodimers that 
function as a repressor at this particular CRE-element.    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17.  Invivo functional analysis of the α7 subunit promoter using luciferase 
reporter gene assay.  The essential promoter -1 to -392 sufficient for transcription 
of the α7 subunit was inserted into the pGL3-b reporter plasmid as represented 
by light bars (pGL3-a7).  The α7 promoter with a crucial CG mutation (pGL3-
ma7) in the CRE half-element was inserted into the pGL3-b reporter plasmid 
shown by dark bars.  The vectors were co-transfected with the reporter plasmid 
pRL-SV40 into SHSY5Y cells and subjected to DMSO vehicle or forskolin (FSK) 
treatment.  Cells were harvested at 48 hours as described in materials and 
methods.  Renilla luciferase produced from the pRL-SV40 vector was used to 
normalize firefly luciferase and expressed as Relative Firefly luciferase activity.         
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Discussion 
To date, there are many missing elements concerning the mechanisms 
involved in the actual transcription of the gene.  When the essential promoter 
region was identified by sequence excising experiments, very few elements were 
immediately denoted as potential regulatory modulators108.  Previously, the rat α7 
promoter was characterized, reporting that the CRE-like element was not 
conserved in this species, even though the entire receptor exhibited high 
homology105.  Further complicating the understanding of the transcriptional 
control of the gene is the existence of alternative splice variants referred to as 
CHRNA7 variants94,95.  In an attempt to contribute to the clarity of transcription, 
this is the first report to our knowledge to characterize the CRE-like element in 
the human promoter.  Consistent with earlier findings, our data support chip 
arrays citing CREB association with the promoter results in down-regulation of 
the receptor after forskolin treatment172,187.  We have shown CREB binding to the 
promoter can be manifested in controlled conditions as well as in a native 
neuronal environment; yet, results suggest that receptor subunit gene expression 
is the result of interactions between proteins that may or may not always directly 
bind the α7 CRE half-element.  It would appear that secondary signaling events 
due to CREB activation results in the production of α7 subunit, yet those same 
events ultimately result in restoring a balance of receptor.   
Treatment with 10 uM forskolin for 24 hours did result in diminished gene 
production as indicated by diminished promoter activity as shown in luciferase 
reporter gene assays.  This supports previous studies using forskolin treatment 
 84 
that resulted in significantly lowering mRNA levels of the α7 receptor172,187.  The 
experimental evidence found here indicates the PKA pathway could be 
responsible for the loss in promoter activity resulting in diminished α7 subunit 
mRNA transcripts.  This brings into question the affinity for the DNA binding site 
for members within the leucine zipper family that could share a high degree of 
homology for this particular sequence of nucleotides.  This is a particularly large 
family of transcription factors consisting of CREB, ATFs, CREMs, and CBP.  It 
should be noted the palindromic consensus CRE-element can not only bind 
CREB but CREB heterodimers or CREM proteins (cAMP-responsive element 
modulators)188.  Also, it has been demonstrated DNA binding heterodimers 
consisting of an activator and repressor can be responsible for repressing 
transcription due to the inability to efficiently bind with co-activators to form 
mediator complexes189.  The occupancy of the CRE-element by either 
homodimer or heterodimer elements acting as repressors could be dependent on 
the activating signals via the PKA pathway resulting in down-regulation of the  
gene.  It has even been postulated that this dimerization and eventual binding to 
DNA can occur regardless of phosphorylation state of the CREB protein resulting 
in an inhibition of cAMP responsiveness that would corroborate our data 
concerning the α7 receptor190.   
Of particular interest from the CREB family is the inducible cyclic AMP 
early repressor (ICER).  It is a splice variant from the CREM gene and is the only 
isoform known to function as an inducible repressor.  ICER has the ability to form 
heterodimers with other members of the CREB/CREM family and inhibit gene 
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expression191,192.  In our studies up-regulation of wild type CREB does induce 
transcription of the gene via the promoter, but not at the CRE half element as 
shown by the mutated α7 promoter.  However, levels of mRNA transcripts are 
diminished by forskolin treatment on the wild type α7 promoter, but levels are 
relatively unchanged in the α7 mutated promoter.  Taken together, this illustrates 
that the CRE half-element investigated does not function as the activating site 
but as the repression site when bound to activated CREB.  It has been shown in 
previous studies that ICER can be induced in particular by forskolin treatment to 
inhibit cAMP responsiveness.  This indicates the alpha7 subunit promoter CRE 
half-element could be under the direct control of an early response repression 
control mechanism via the PKA pathway.  Illustrated in Figure 18 are two 
potential CREB pathways resulting in very different transcriptional control 
outcomes.   
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Figure 18.  Possible CREB pathways associated with α7 expression.  A 
schematic flow chart representing the possible signaling pathways that CREB 
activation could be involved in self-regulated gene expression using interactions 
between CREB and CREM isomers.   
 
     Control mechanisms involving the CRE-element could contribute to the 
precise expression pattern exhibited by the gene.  Receptor identification in 
human was limited to the central nervous system, althought it has been recently 
identified in leukocytes, endothelial cells (ECs), bronchial epithelial cells, skin 
keratinocytes, and vascular smooth muscle.  In particular, regions in the brain 
found to have high expression levels are the nucleus reticularis of the thalamus, 
the lateral and medial geniculate bodies, the basilar pontine nucleus, the 
horizontal limb of the diagonal band of Broca, the nucleus basalis of Meynert, 
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and the inferior olivary nucleus.   Recently, functional differences are found to 
exist between leukocyte α7 receptors and CNS α7 receptors, indicating 
processing at some level is responsible for functional changes.  The α7 receptors 
in the CNS are involved cell signaling through direct calcium permeability, while 
those in leukocytes function as secondary messengers signaling via co-
expression with a T-cell receptor/CD3 protein92.  If functional differences are 
prevalent based on tissue specific expression patterns, the issue remains to find 
what control mechanisms are directly responsible for this.  Further studies remain 
to not only further understand the overall transcriptional control of the promoter 
but to also determine if the CRE-half element characterized in this study 
participates in tissue specific expression.       
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CHAPTER 5 
CONCLUDING REMARKS 
   The chemical and biological abnormalities found in schizophrenia are the 
intense focus of much current research associated with schizophrenia as well as 
in these studies.  The molecular differences with regard to the α7 receptor 
observed in schizophrenia were of particular interest to this investigation.  
Diminished α7 receptor functioning is one of the few known deficient molecular 
mechanisms associated with a subset of patients in schizophrenia.  This finding 
could be the result of an autoimmune response or dysfunctional regulatory 
mechanisms in a group of patients affected with the disorder.  The results of the 
present research should help us to better understand the role of the α7 receptor 
as a potential contributing factor in the complex etiological mechanisms that 
contribute to the pathophysiology observed in schizophrenia. 
  
Recombinant Expression of the α7 Nicotinic Receptor 
 In the first study, the recombinant production of the receptor was 
investigated.  Regulation of the α7 gene undergoes extreme control in order to 
exhibit the complex pattern of expression associated with it.  Resolving the 
essential elements involved in receptor production is essential to understanding 
the pathophysiology the receptor displays in schizophrenia as well as creating a 
source of the receptor for experimental studies.  The α7 subunit is a four 
transmembrane region protein, with large extracellular and intracellular 
components when tethered together with four more subunits form a homomeric 
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ligand-gated ion channel.    The receptor is hydrophobic, and this feature likely 
contributes to the difficulty in its isolation.  It is possible the concentration of 
subunit directly affects receptor ion channel formation.  Next, the post-
translational processing is dominated by signaling and chaperoning proteins to 
properly transport the product to the membrane.  Also, there are additional 
tethering proteins found in the membrane to anchor the receptor correctly that 
affect expression.  Recently, proteins have been found to co-express with the 
nAChRα7 that may participate in specific cell signaling events, which further 
complicates recombinantly producing the receptor (see Chapter 2).  The complex 
sequence of events required to form functional channels results in many areas 
that could be potentially deficient in current molecular recombinant methods.   
These factors severely hampered efforts to recombinantly express the 
receptor.  Insect cells were initially used based on their ability to properly add 
post-translational modifications, initiate correct protein folding, exhibit high levels 
of protein expression, and survival in low-stringent conditions.  Unfortunately, the 
complexity of nAChRα7 receptor expression could not be overcome in this 
system.  Attempts to produce the entire recombinant receptor in high-yield insect 
cells using a viral vector were unsuccessful.  This was not surprising, due to the 
lack of any literature successfully citing recombinant α7 receptor production in 
insect cells.  Concurrent with insect cell expression, attempts to express the 
entire receptor in commercial systems were used.  The rabbit reticulocyte 
expression system from Promega and the insect cell system from Qiagen were 
both empolyed in full-length a7 subunit expression without success.  With the 
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formation of entire receptor not an option, the next suitable idea was to express 
pieces of the receptor.  The first 200 amino acids make up the extracellular 
portion of the a7 subunit.  This was the only portion of the subunit that was 
successfully expressed in the commercial systems but was not successfully 
produced in the insect system chosen (Figure 19).  Further investigation by 
expression of distinct parts of the receptor in indicate the membrane region, 
along with the carboxylic terminal, cannot undergo the proper modifications 
needed for production in any system other than a mammalian system.  However, 
the knowledge gained from these attempts will be instrumental in future studies 
to elucidate the potential biological mechanisms needed in completing the picture 
regarding nAChRα7 expression, noted in Chapter 2.  But until the precise 
regulatory mechanisms controlling the α7 receptor expression are identified, 
mammalian cells and frog oocytes are the only options in recombinant 
expression of the functional α7 receptor.   
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Figure 19.  Recombinant α7 protein.  The α7 recombinant subunit is a four-
transmembrane spanning protein.  The arrow pointing to the ellipse is the only 
portion of the receptor that was recombinantly produced, the first 204 amino 
acids. 
 
 
Autoimmunity in Schizophrenia 
The second study investigated the presence of antibodies in the 
schizophrenic patient population that could be responsible for impaired neuronal 
functioning.  The success of this study was contingent on the ability to produce 
recombinant α7 subunit in it’s full-length form with an identifying marker or tag 
that could be used in an ELISA method (see Chapter 3 methods).  Only the 
extracellular portion was available based on the previous experiments.  However, 
a commercially produced recombinant truncated version of the protein, with more 
amino acids of the subunit, became available during our efforts.  Used in the 
previous experiments, as shown in Chapter 3, was a partial α7 subunit (318 
amino acids) expressed in wheat germ extract.  This was the best available 
source of the receptor, with a portion of the transmembrane region included in 
expression.  The protein was produced in a wheat germ expression system.  This 
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made it possible to adjust for anti-human reactivity in the wheat germ molecules.  
There was specific binding to indicate the subunit can be differentiated through 
bungarotoxin and antibody identification as an α7 subunit.  The results of the 
experiments, where the truncated a7 subunit was used, indicated there may be 
an antibody specific for the α7 subunit, seen in at least of a subset of patients 
affected with schizophrenia (Figure 20).   
 
 
 
 
 
 
 
 
 
Figure 20. ELISA assay utilized to determine sera IgG levels against α7 receptor 
in Schizophrenics.  ELISA assay determined differences in Sera IgG levels 
specific for the α7 receptor in schizophrenic patients and controls.   
 
The presence of an antibody could contribute in many different ways to 
disease neuropathology.  Initially, the antibody may be functioning as the body’s 
own antagonist.  The functional α7 receptor is responsible for cell signaling 
involved in the propagation of action potentials, ultimately ending in modulation of 
neurotransmitter release.  If an antibody were to bind to the receptor, the initial 
effects could impede ligand binding or ion movement through the channel, both 
events impairing α7 signaling events that would occur downstream.  This would 
compromise neurotransmitter release or interactions.  The mechanisms behind 
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α7 receptor controlled neurotransmission are poorly understood, so it would be 
hard to identify specific potential effects at this time.  Myasthenias Gravis is an 
example of an autoimmune disorder acting in this manner.  Self-produced 
antibodies block the acetylcholine receptors found in muscle inhibiting 
acetylcholine binding that results in muscle weakness, particularly of the facial 
muscles.    Also, an antibody binding event may target the cell for destruction.  
The patient’s immune system could be inducing cellular degradation of the target 
tissue.  An example of this is found in multiple sclerosis.  Antibodies bind 
specifically myelin basic protein as well as other oligodendrocyte proteins.  This 
event leads to the eventual loss of oligodendrocytes, resulting in demyelination of 
axons in the CNS.   In schizophrenia, such an antibody event would explain the 
reduced brain volume noted in the disease.  An antibody specific to the α7 
receptor could result in a loss of a particular cell population.  There are specific 
deficiencies noted in GABA functioning that indicates potential loss of 
hippocampal neurons noted in schizophrenia193.  The neurons are responsible for 
the release of the inhibitory neurotransmitter GABA.  The α7 receptors role in 
GABA modulation is not well-known, but receptor activation by acetylcholine 
does participate directly in release of the neurotransmitter55.  Alternatively, an 
antibody could be acting as an allosteric modulator in which the α7 receptor was 
in a constant state of operation.  The channel would allow more calcium signaling 
events to occur resulting in an over-activation of the cell.  This would fit the 
glutamate excitotoxicity hypothesis in schizophrenia.  This theory states in 
schizophrenic brains there is constant glutamate release that literally excites cells 
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to death, resulting in slow neurodegeneration (Stahl, 2nd edition).   Lastly, an 
antibody specific for the α7 receptor could be present during prenatal or early 
childhood neuronal development.   The antibody could be interfering with the 
delicate neuronal processes occurring at this time, resulting in the cognitive 
deficits noted later in the disease.   
However, the validity of these findings will always be questioned until a 
completely pure source of the entire receptor can become available.  The 
experimental data obtained only useed 60% of the α7 subunit to probe human 
sera for antibody binding (Figure 21).  Human α7 receptor from native cells is not 
a good source at this time.  Extraction of the nAChRα7 from brain or neuronal 
cells with current methods leads to a very impure source of the receptor.  This 
source of receptor leads to high amounts of suspected nonspecific interactions 
with human sera that cannot be controlled.  To clarify, there is the same amount 
of antibody or more antibody binding in cells that do not endogenously produce 
the receptor than those containing α7 receptor (Figure 22).  Nicotinic receptors of 
the nAChRα3 heteromeric type, tubulins, and other cytoskeletal proteins have an 
affinity for the compounds used to isolate and purify recombinant nAChRα7.  
Selective ligands that were used to initially characterize recombinant α7 
receptors in early studies behave pharmacologically different in native systems92.  
This questions the selectivity of the α7 receptor purified from brain tissue as a 
true source of the receptor, further casting doubt on identification of an antibody 
specific for the receptor.  Also, the α7 receptor is no longer thought to be a 
homomeric channel.  The α7 subunit could be forming ion channels with α3 
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subunits120.   The antibody identified in this particular study only explores binding 
to a portion of a recombinant subunit, not to a functional α7 homomeric nicotinic 
receptor.   This antibody should be validated in future studies to a pure source of 
the α7 receptor.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 21.  Antibody specificity to recombinant α7 receptor amino acid sequence.  
The antibody binding is specific to only the truncated α7 subunit that was 
produced recombinantly in wheat germ extract and verified by Western blotting.  
The green boxes are the membrane spanning regions of the subunit.  The 
truncated version did not possess the intracellular portion or the last 
transmembrane region.  The subunit did not form functional receptor, as shown 
by the circles.  
  
The results from the patient sera evaluation do suggest an increase in 
antibody specific for the truncated α7 subunit with age in the schizophrenic 
population.  If a more suitable source of the α7 receptor became available, better 
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evaluations of environmental triggers, pharmacological treatments, symptom 
manifestation, and disease susceptibility could be evaluated through α7 antibody 
titer levels.  The patho-physiology of nAChRα7 is implicated in many other 
diseases, such as Alzheimer’s disease and autism.  It may be possible to use 
this assay in those diseases as well to probe for an antibody contribution in their 
disease physiology.  Future studies are necessary to support the results 
obtained, but this work certainly opens the door for ideas to be revisited 
concerning an auto-immune basis for schizophrenia, which has generally been 
disregarded in recent years. 
 
 
 
 
 
 
 
 
 
 
 
Figure 22.  SHEP1 and SHEP1-pCEPa7 cells in α7 autoantibody evaluation.  
This is a sample sera dilution curve that represents the amount of nonspecific 
binding that occurred when human serum antibodies were incubated with 
membrane fractions from the epithelial cells, SHEP1, that were null α7 (light 
bars) or epithelial cells, SHEP1a7, that recombinantly produced α7 (blue bars).   
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Transcriptional Regulation of the α7 Receptor 
 There are many factors that affect proper expression of functional alpha7 
receptors in human cells.  Subunit concentration and specific molecular 
chaperone proteins were two of those factors mentioned previously.  The 
expression of the α7 subunit is crucial in understanding receptor pathophysiology 
in schizophrenia.  The precise mechanisms that result in a functional α7 receptor 
are poorly understood.  This led to the final investigation that examines 
transcriptional regulation of the α7 receptor subunit.  The study identified a 
functional transcriptional cyclic AMP response element (CRE) in the promoter of 
the α7 subunit gene that was previously uncharacterized.  The CRE half element 
was shown to sufficiently bind the transcription factor in both in-vitro and in-vivo 
studies.  Protein interactions with the CRE half-element directly affect 
transcription of the receptor that was shown through luciferase reporter gene 
assays.  Overall, it was found the protein binding events with the α7 CRE-half 
element involves a complex interaction between multimeric CREB dimer proteins 
that could act in a negative feed-back regulatory manner in the transcription of 
the α7 subunit (Figure 23). 
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Figure 23.  Potential interactions between CREB isomers and the nAChRα7 
promoter.  The interaction between cyclic AMP response element binding protein 
(CREB) and other proteins determine transcriptional events of the α7 gene.  
CREB dimers may result in activation of the α7 gene, while heterodimers formed 
with inducible cyclic AMP early repressor (ICER) would repress transcription.  
  
 The transcription of the α7 subunit is extremely important in functional 
receptor formation.  Receptor subunit concentration may play a role in proper 
receptor expression.  The transcription of different nicotinic receptor subunit 
genes involves a complex interaction of control elements that have yet to be 
identified.  This transcription factor CREB and the possible association with 
repressor elements may be a distinct regulatory mechanism of the α7 subunit.  
The α7 receptor has been thought to induce phosphorylation of the CREB 
transcription factor upon ligand binding, although this has not been well-
supported.  It would then be plausible to consider that the effects of this event 
may induce a positive and negative regulatory mechanism, which is different than 
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previously thought.  Initially, ectopic CREB expression allows the receptor to be 
expressed at functional levels; even upon up-regulation of wild type CREB there 
is an increase of alpha7 subunit gene expression (Chapter 4).  But at a certain 
level CREB phosporylation begins to participate as a repressor to effectively 
control the levels of α7 receptor after induction of the PKA pathway.  This has 
been demonstrated in other neurotransmitter receptors, most notably in the 
GABRA1 receptor where an interaction between CREB homodimers and 
heterodimers control receptor subunit expression 194. 
 Any upset of this regulatory mechanism could result in inefficient subunit 
production and ultimate loss in functional receptor.  Dr. Sherry Leonard and her 
associates have shown functional polymorphisms in the promoter region affect 
α7 receptor subunit transcription.  These nucleotide changes have been 
implicated in the auditory gating deficit found in schizophrenia.    Two of the 
functional SNPs are found on either side of the α7 subunit CRE half-element108.  
Future studies could evaluate the effect of the identified SNPs on proper CREB 
transcriptional complex formation.  Also, it is important to establish the exact 
signaling mechanisms involved in α7 activation of CREB that results in α7 
subunit gene repression through direct binding to the CRE half-element found in 
the promoter region.  These studies could focus on the Calmodulin-CREB 
pathway and further define the precise relationship to nAChRα7 expression.  
Evaluation of the association of CREB with the α7 receptor indicates the need to 
explore the receptor’s role in secondary cell signaling events.   This opens all 
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sorts of venues to explore concerning the exact role the receptor occupies in 
neuronal as well as peripheral signaling.   
 In summary, the findings here indicate the α7 nicotinic receptor does play 
an important role in the pathophysiology of schizophrenia.  These studies support 
the general notion that the improper functioning of the nAChRα7 receptor, 
whether by aberrant transcription or dysfunctional physiology by auto-antibody 
binding, could contribute the neurophysiology of the disease, at least in a 
percentage of patients.  The advent of better molecular tools by which to study 
the physiology of the nAChRα7 receptor and the release of more information 
regarding the specific function of the receptor will not only further our 
understanding of the precise mechanisms the receptor occupies in schizophrenia 
but hopefully lead to the development of a better prognosis overall.     
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